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Abstract 
 
Retinitis Pigmentosa (RP) is an inherited photoreceptor degenerative disease that leads to 
blindness and affects about 1 in 4000 people worldwide. The disease is predominantly 
caused by mutations in genes expressed exclusively in the night active rod 
photoreceptors; however, blindness results from the secondary loss of the day active cone 
photoreceptors, the mechanism of which remains elusive. Here, we show that the 
mammalian target of rapamycin complex 1 (mTORC1) is required to delay the 
progression of cone death during disease and that constitutive activation of mTORC1 is 
sufficient to maintain cone function and promote cone survival in RP. Activation of 
mTORC1 increased expression of genes that promote glucose uptake, retention and 
utilization, leading to increased NADPH levels; a key metabolite for cones. This 
protective effect was conserved in two mouse models of RP, indicating that the secondary 
loss of cones can be delayed by an approach that is independent of the primary mutation 
in rods. However, since mTORC1 is a negative regulator of autophagy, its constitutive 
activation led to an unwarranted secondary effect of shortage of amino acids due to 
incomplete digestion of autophagic cargo, which reduces the efficiency of cone survival 
over time. Moderate activation of mTORC1, which promotes expression of glycolytic 
genes, as well as maintains autophagy, provided more sustained cone survival. Together, 
our work addresses a long-standing question of non-autonomous cone death in RP and 
presents a novel, mutation-independent approach to extend vision in a disease that 
remains incurable. 
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CHAPTER I 
 
Introduction 
 
The neural retina and photoreceptors:  
The retina is a neuro-epithelial tissue that is situated at the back of the eye and initiates 
the process of vision1. Three nuclear layers characterize the tissue, each comprising of 
groups of highly specialized neurons (Figure 1.1 A and B)2-4. The photoreceptors (PRs) 
constitute about 75% of all retinal cells and are specialized to capture photons of light in 
an elaborate structure referred to as the outer segment (OS) (See Figure 1.1 C). The OS is 
densely packed with lipids and proteins known as opsins, which are 7 transmembrane G-
protein coupled receptors that covalently bind the light-sensitive chromophore (retinal), 
which mediates the absorption of light5-7. In addition to the OS, PRs also have an inner 
segment (IS), which constitutes the cytoplasm of the cell and is rich in mitochondria8. 
The cell bodies of the PRs are located in the outer nuclear layer (ONL).  
 
There are two types of PRs that contribute to vision, rods and cones. In the human and 
mouse retina, the distribution of rods and cones is such that rods make up about 95-97% 
of the total PRs, while cones account for the remaining 3-5%2,9. The rod PRs can be 
activated by a single photon of light, however they become unresponsive upon constant 
light exposure and hence mediate only dim light or night vision10. 
                                                 
2             
            Figure 1.1: Human eye and retinal cell types: Schematic of the human eye (A) and haematoxylin and 
eosin staining of a mouse retinal cross section (B) showing the various retinal neurons and the retinal 
pigment epithelium above. The photoreceptor (PR) cells that initiate the process of vision are of two types, 
rods and cones. A schematic of a PR cell is illustrated in (C). PRs possess an elaborate structure comprising 
of an outer segment (OS), inner segment (IS) and their nuclei are located in the outer nuclear layer (ONL). 
(INL: inner nuclear layer, GC: ganglion cell, GCL: ganglion cell layer) 
 
The cone PRs on the other hand, are about 100 times less sensitive to light when 
compared to rods however, unlike rods they have faster response kinetics and hence can 
function upon constant light exposure7. Therefore, cones mediate daylight vision. In 
humans, there are three types of cones that are distinguished by the presence of specific 
opsin proteins that promote the absorption of light of short (blue), medium (green) and 
long (red) wavelengths, which allows for highly specialized color vision7,11. Each cone 
expresses only one of the 3 opsins (blue, green or red). On the contrary, rods possess only 
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one opsin known as rhodopsin, which absorbs light in the medium wavelength range. 
Humans possess a cone-rich region in the center of the retina known as the macula, which 
confers high-acuity central vision11. In contrast, mice have no macula and only two cone 
opsins that recognize either short or medium wavelengths of light12,13. Cones located in 
the ventral region of the retina in mice however, express both opsins.  
 
Upon absorption of a photon by a PR cell, there is a cascade of biochemical events that 
converts the captured light into an electrochemical signal. This process is known as 
phototransduction14,15. The signal from PRs is then passed on to bipolar cells, which are 
located in the inner nuclear layer (INL) and from there, to neurons in the ganglion cell 
layer (GCL). The axons from the GCL converge to form the optic nerve, which outputs to 
the visual centers in the brain15. In addition to bipolar cells, the INL has horizontal and 
amacrine cells, which serve to modulate the visual response3. The retina also has a glial 
cell type known as the Müller glia, which traverse the entire tissue and form the blood 
retinal barrier16. The neurons in the INL and GCL receive nutrients and oxygen from the 
retinal vasculature (Figure 1.1 A). However, the PRs are primarily located in an avascular 
area, and the nourishment for these cells is derived from the retinal pigment epithelium 
(RPE), which in turn obtains nutrients from the choroidal vasculature above17,18. RPE 
cells possess microvilli, which are in close association with PR OSs to mediate the 
transfer of nutrients and oxygen. The RPE also plays a critical role in the regeneration of 
the chromophore that is required for the visual cycle. Once a photon hits the 
chromophore, there is a cis to trans isomerization that occurs, which needs to be reversed 
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to allow for the absorption of a new photon. This involves the shuttling of the 
chromphore to the RPE, where the isomerization is reversed and then transported back to 
the PR OSs19. Moreover, PRs are known to shed about 10% of their OS every day, which 
is phagocytized by RPE cells20,21. Therefore, RPE cells are critical for the normal 
functioning of PRs and we will describe these in more detail in subsequent sections of the 
thesis. Finally, RPE cells are packed densely with pigment granules known as 
melanosomes, except in albinos, where there is no pigmentation. Melanosomes help in 
the absorption of scattered light, thereby improving the efficiency of the optical system 
and reducing photo-oxidative stress22.  
 
Since PRs constitute about 75% of all retinal cells2,3 and are required to initial the visual 
response, diseases that cause blindness often arise from loss of PRs and these may be 
caused due to genetic defects (inherited) or a combination of genetic and environmental 
risk factors (acquired).  We will focus of inherited PR diseases, which can be broadly 
classified as cone, cone-rod or rod-cone dystrophies23. In the case of cone dystrophy, the 
disease-causing mutations are expressed in cone-specific genes, while in cone-rod 
dystrophy; the diseased genes may be expressed in both PR cell types. In either condition, 
cones are preferentially affected, leading to loss of daylight and color vision. However in 
some cases of cone-rod dystrophy, both rods and cone may degenerate simultaneously. In 
case of rod-cone dystrophy, mutations are in genes that are expressed exclusively in rods 
or in both PR cell types, but preferentially affect rods. Interestingly, in humans and mice, 
loss of rods is always followed by the degeneration of cones, but loss of cones has a 
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negligible effect on rods24-27. Therefore, even if the mutation only affects the night-active 
rod PRs, cones degenerate as well leading to the secondary loss of daylight vision. This is 
particularly interesting because other neurons such as bipolar cells or horizontal cells 
which form synapses with rods are not affected until the end stages of blindness28, which 
raises the question as to why cones are preferentially affected upon loss of rods. Besides 
being a fundamental question in retinal biology, it is also critical to understand the 
mechanism of this secondary cone death as it plays a critical role in the retinal 
degenerative disease Retinitis Pigmentosa, which is the focus of this thesis. 
 
Retinitis Pigmentosa:  
Retinitis Pigmentosa (RP) is a group of inherited retinal diseases that lead to blindness 
due to the loss of rod and cone PRs. The disease has a prevalence of about 1 in 4000 
people worldwide and affects more than 1 million individuals29. In about 50-60% of 
cases, the disease is inherited as an autosomal recessive trait, while it is autosomal 
dominant in 30-40% and X-linked in about 10% of cases29. The term ‘Retinitis’ is a 
misnomer since the term ‘-itis’ is generally used to denote inflammation. While the initial 
perception was that RP was an inflammatory disorder, it is now clear that this is not the 
case and there are clear genetic factors that cause it30. ‘Pigmentosa’ on the other hand, 
was used to denote the appearance of pigmentation due to RPE cells that migrate into the 
neural retina following loss of the PRs30,31. This can be observed by fundus photographs 
of the eye and is also illustrated in Figure 1.2 B. 
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Thus far, over 60 genes have been identified that when mutated cause RP (RetNet: 
https://sph.uth.edu/retnet/). While most of these are PR-specific genes, there are 
exceptions to this. For example, MERTK (mer tyrosine kinase proto-oncogene) is a gene 
that is expressed in RPE cells and is involved in phagocytosis of the PR outer segments. 
Mutations in this gene cause autosomal-recessive RP due to accumulation of debris in the 
sub-retinal space, which is the area between the PRs and the RPE32. Additionally, 
dominant mutations in genes such as PRPF8 and PRPF3 (pre-mRNA processing factor) 
are ubiquitously expressed33,34, however they preferentially affect PRs, the reason for 
which still remains enigmatic29. Moreover, there are instances where patients with RP 
develop other complications, in which case it is classified as a syndrome. The most 
common syndrome is Usher’s syndrome where visual dysfunction is accompanied by 
hearing impairment. Another example of syndromic RP is Bardet-Biedl syndrome, where 
RP is associated with other complications such as obesity, renal disease and other 
developmental delays35. 
 
Most RP patients harbor mutations in rod-specific genes due to which RP is synonymous 
with rod-cone dystrophy29 (RetNet: https://sph.uth.edu/retnet/). Among these, mutations 
in the RHODOPSIN (RHO) gene alone account for about 25% of the cases of autosomal-
dominant RP29,30. The disease has a variable onset, with some patients developing vision 
loss in childhood, while most patients do not experience any apparent symptoms until 
mid-adulthood36. Patients first experience night blindness from the loss of rod PRs, 
followed by a condition known as tunnel vision, where peripheral vision is lost due to 
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degeneration of cone PRs in the peripheral areas of the retina. The central region of the 
retina, which has the cone-rich macula, is always the last to deteriorate in cases of rod-
cone dystrophy30. 
 
In majority of RP cases, patients are unaware of the initial night blindness because in 
today’s modern world with electricity, there is almost no requirement for night vision. 
However, by the time this stage is reached, there is already severe reduction in cone 
function, even prior to loss of cone PRs. In fact, a measurement of visual function using 
electroretinography (ERG) shows that patients as early as 6 years of age already show a 
decline in visual function, although they do not show any apparent symptoms of RP until 
adulthood36. The ERG measures the electric response that is produced to a light stimulus 
and is recorded by placing electrodes on the surface of the eye29. The ERG allows for 
early detection of the disease, evaluation of disease progression and its response to 
treatment36-38. Figure 1.2 (A) illustrates examples of ERG recordings from mice with and 
without RP. The mouse model of RP illustrated here is the retinal degeneration-1 (rd1) 
model39 and a rapid decline in light-adapted ERG recordings is observed as early as 
postnatal day (P) 21 in this model, a time point when cone death has just initiated13,40. We 
will describe this model in further detail during subsequent sections of the thesis. 
Additionally, there are other techniques that may be used to measure the extent of PR 
degeneration. Optical coherence tomography (OCT) measures the thickness of the ONL 
and allows for evaluation of retinal morphology in vivo41. Fundus photography, 
performed with an ophthalmoscope allows the physician to obtain images of the back of 
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the eye, in order to detect pigment granule deposition which are indicative of late stages 
of RP31. Figure 1.2 (B) shows fundus photographs from wild type and rd1-mutant mice to 
illustrate the pigmentation that is observed in RP. Attenuated blood vessels and optic disk 
pallor are also observed at this stage30,36. Finally, due to its genetic inheritance, the family 
history of the patient also plays an important role in the diagnosis42. 
             
Figure 1.2: Pathological features of RP in mice. (A) Representative photopic (light-adapted) ERG 
recordings from wild type and rd1 mice. The Y-axis represents the current that is produced in the retina 
following a light stimulus and is plotted against time after which the stimulus was applied (X-axis).  In 
response to a light stimulus, the PRs hyperpolarize resulting in a negative deflection (arrowheads) known 
as the a-wave. This is followed by depolarization of the post-synaptic bipolar cells, producing a positive 
deflection (arrow) known as the b-wave43,44. The amplitude of the b-wave is measured from the trough of 
the a-wave to the peak of the b-wave45 and is commonly used as a readout of retinal function. ERG 
responses from rd1 mice are very low as early as post-natal day 21 (P21). (B) Representative funduscopy 
images from wild type (above) and rd1 mice (below) at 2 months of age, where retinal pigmentation 
deposits becomes visible.  
9
Despite the advances made in the identification of genes responsible for RP, there is 
currently no effective treatment for the condition apart from limited success obtained 
with vitamin and dietary supplementation29. The aldehyde form of Vitamin A is retinal, 
which forms the visual chromophore, critical for PR function46. Clinical trials where 
patients with RP were administered high doses of Vitamin A (15,000 IU per day) showed 
modest improvement in visual function as measured by ERG recordings and visual acuity 
tests38,47. Apart from Vitamin A, studies were conducted with docosahexaenoic acid 
(DHA), an omega-3-fatty acid that forms an important component of the PR 
membranes48. Although DHA supplementation did not show any significant improvement 
in RP patients49,50, another study found that RP patients had significantly lower 
concentrations of DHA in their red blood cells when compared to healthy controls51. 
Recently, a clinical trial reported that X-linked RP patients with DHA supplementation 
showed modest improvement in visual field tests52. However, none of these trials were 
tested for durations beyond 4-6 years and hence the long-term effects of Vitamin A or 
DHA supplementation are unknown. Also, continuous intake of high doses of vitamins 
may not be beneficial to the overall health of individuals53-55. More recently, gene 
replacement strategies using viral vectors have entered clinical trials. The most successful 
example of gene replacement in humans so far is for Leber’s congenital amaurosis-2, a 
special case of early onset RP caused by recessive mutations in RPE65 (retinal pigment 
epithelium-specific 65kDa protein), a gene that is required for proper functioning of the 
RPE56. Proof of concept studies for the therapy in dogs yielded extremely promising 
results with restoration and preservation of visual function for up to 11 years following 
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gene delivery57-62. While treated patients displayed improvements in visual function, these 
effects did not persist long-term for all patients and they continued to exhibit PR loss63,64. 
One could speculate several reasons for the limited success in humans such as inefficient 
vector transduction and/or late stage of intervention when there is already significant PR 
loss. Therefore, more detailed understanding of the pathology and progression of the 
disease are critical to develop stage-specific therapies to delay loss of vision. Over the 
last few decades, several efforts are being made in this direction and these can be broadly 
classified into three categories, which are related to the stages of progression of the 
disease, as depicted in Figure 1.3. 
 
Figure 1.3: Stages of therapeutic intervention for RP. This thesis is focused on understanding the 
mechanism of secondary cone death, which follows the initial loss of rod PRs. (Figure modeled from Punzo 
et al, 201265) 
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Stages of therapeutic intervention for RP: 
 
1. Inhibition of rod or early PR death 
2. Inhibition of secondary cone death 
3. Restoration of visual sensitivity by optogenetics 
 
We will elaborate on each of these approaches, with special emphasis on the second 
approach, since that forms the basis of this thesis.  
 
1. Inhibition of rod death: 
The first approach is to prevent or delay rod death, since rods are the PRs that are 
affected first in most cases and preventing rod death would also inhibit secondary loss of 
cones. The most straightforward strategy is to replace the diseased gene with a normal 
allele in cases of recessive RP66-68. For dominant RP, this would involve using approaches 
like RNA interference (RNAi) or ribozyme to silence the dominant allele69-71. While these 
strategies have been successfully employed in animal models, translating this to humans 
would depend on establishing clinical studies for every gene. About 60 disease-causing 
genes have been identified to cause RP and yet, these represent only about 60% of the 
patient population29. Therefore, mutation-independent approaches that allow different 
patient groups to be treated with a similar strategy represent a more feasible and practical 
alternative to this approach. This however depends on a deeper understanding of the 
disease mechanism in order to identify targets for therapeutic intervention that can be 
applied to a broad spectrum of disease mutations.  
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Mutation-independent approaches to delay PR death: 
Many disease-causing genes in RP are part of the rod phototransduction pathway or 
encode structural components of the rod outer segments. Recessive mutations in these 
genes therefore affect normal PR physiology. One example is cGMP phosphodiesterase, 
an enzyme that forms a critical component of the visual cascade, the absence of which 
leads to the accumulation of cGMP and elevated levels of calcium, leading to PR cell 
death40,72,73. Loss of this enzyme can be caused due to recessive mutations in PDE6A or 
PDE6B genes29,72,74. The rd1 mouse model of RP that was discussed briefly previously 
also harbors a loss of function mutation in the Pde6b gene. In cases of dominant RP, 
many patients are affected by mutations in RHODOPSIN. PR death in such cases is due 
to misfolding and/or aggregation of mutant RHODOPSIN or from a defect in the 
structure of the outer segments29,75-77. While the primary cause of degeneration in these 
cases is different, studying the downstream effects of the cellular response may lead to 
the identification of targets that can be employed to delay PR loss. In this regard, 
understanding the mechanism of execution of cell death has been an attractive avenue of 
research. Under various stress conditions, apoptosis, which is a form of programmed cell 
death, is known to be the main mechanism of rod cell death13,78. Apoptosis is executed by 
cell death proteases called caspases, which recognize specific sequences in their target 
proteins and cause their cleavage79. The X-lined inhibitor of apoptosis (XIAP) is a protein 
that can bind to caspases and inhibit their function80. In this regard, over-expression of 
XIAP using recombinant adeno-associated viral (rAAV) vectors has been shown to 
protect PRs both structurally as well as functionally in dominant models of RP, caused by 
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the P23H or S334ter mutations in the Rhodopsin gene81. Further, in the rd10 mouse 
model of RP, which is also caused by a loss of function mutation in the Pde6b gene82, 
XIAP was able to improve the efficiency of gene-replacement with the Pde6b gene83. 
Moreover, rAAV mediated over-expression of XIAP in rod precursor cells has also been 
shown to extend their survival when transplanted into a degenerating mouse model of 
RP84. Cell transplantation based therapies using PR precursor cells are an active area of 
research to replace PRs in a mutation-independent manner and encouraging results have 
been obtained by these approaches in animal models85-87. However, the long-term survival 
of the newly transplanted donors in a degenerating environment may be a hurdle and 
supplementation with XIAP or other mechanisms to extend their survival may improve 
their efficiency. 
 
Another approach to delay PR death is through the administration of neuroprotective 
factors such as brain derived neuroprotective factor88, glial cell-line derived 
neuroprotective factor89 and the ciliary derived neuroprotective factor (CNTF)90-92, all of 
which confer neuroprotection in animal models of RP. Among these, CNTF has been 
extensively studied and shown to be effective in various animal models of RP, although 
its mechanism of action is not understood yet. A recent study showed that gene therapy 
with Cntf conferred long-term protection to both rod and cone PRs in a mouse model of 
RP93. The positive data from these experiments have encouraged clinical trials for late 
and early stage RP where capsules are implanted into the eye to release CNTF 
(NCT00447980 and NCT00447993, from clinicaltrials.gov). The data from animal 
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models as well as results of the clinical trials may further encourage the development of 
gene therapy strategies using CNTF.  
 
Another approach to delay PR death has been through the use of the histone deacetylase 
Hdac4, the expression of which has been shown to delay both rod and cone death and 
restore function in the rd1 mouse model of RP94,95. However, the ability of Hdac4 to 
extend PR survival in other models remains to be tested.  
 
A recent and rather creative approach to delay PR death leverages a specific 
developmental difference between rods and cones. The neural retina-specific leucine 
zipper protein (NRL) is expressed in PR progenitor cells that are fated to become rods96. 
In the rd1 mouse model, removing Nrl from adult rods caused them to become more 
cone-like, making them less vulnerable to the primary mutation, thereby improving PR 
survival as well as function97. This approach can principally be applied in a mutation-
independent manner to any rod-specific mutation.  
 
Collectively, these studies show that it is possible to target common nodes in the rod 
degeneration process and that mutation-independent approaches a more attractive 
strategy for therapeutic intervention. However, since most of these approaches are 
targeted towards rescuing the rods, they would have to be applied prior to the loss of 
most rods. As previously discussed, diagnosis of RP at the initial stages of night 
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blindness is often rare, which limits the window of therapeutic intervention for these 
approaches.  
 
2. Inhibition of secondary cone death: 
Since rod death is always followed by cone death in humans and mice, and because cones 
are the neurons that mediate daylight vision, strategies that delay death of cone PRs 
would be an alternative option to extend vision. However, developing a strategy to delay 
cone death requires understanding of the mechanism(s) of secondary cone death. Since 
cone death occurs irrespective of the primary mutation in rods, the reason(s) for cone 
death is likely to be the same across various rod-specific mutations. Many theories have 
been proposed to explain the interdependence of cones on rods. Such theories include the 
secretion of toxic products by dying rods or overactive microglia recruited to remove 
dying rods secrete toxins that are harmful to cones98,99. However, the kinetics of rod and 
cone death suggest that this is an unlikely scenario, since cone death does not initiate 
until the final stages of rod death13. If cones were dying due to toxic byproducts, cone 
death should have initiated during the major phase of rod death and not after most rods 
have died. Another theory is the absence of a trophic factor that is secreted by rods and is 
required for cone survival100-102. There is also a proposition that once rods are lost, cones 
are exposed to higher levels of oxygen from the choroidal vasculature above, resulting in 
increased oxidative stress103-105. Our laboratory recently proposed a different theory 
suggesting that cones suffer from a nutrient shortage induced by disruption of the retinal 
architecture once most rods have been lost13. Our model as well as the oxidative stress 
16
and trophic factor models are not mutually exclusive and we will elaborate further on 
these below.   
 
A. Oxidative stress model: 
Like all neurons, PRs require large amounts of ATP to re-equilibrate their membrane 
potential, since they constantly hyperpolarize in response to light106,107. This requirement 
is higher for cone PRs since they are active throughout the day, as opposed to rods. 
Concordantly, cones in mice have nearly twice the number of mitochondria as rods, while 
this number is increased ten-fold in primates108,109. The high rate of mitochondrial activity 
is accompanied by the generation of reactive oxygen species (ROS), which are formed as 
a byproduct of mitochondrial metabolism110. Further, PRs are constantly exposed to the 
ultraviolet radiation from sunlight and the reactions involving the chromophore as part of 
the visual cycle result in the generation of free radicals111-113. In order to counteract the 
oxidative stress, the inner segments of PRs are packed with antioxidant enzymes such as 
superoxide dismutase and glutathione peroxidase8,112. On the contrary, PR outer segments 
have evolved a natural mechanism to eliminate oxidized lipids and proteins. PRs shed 
about 10% of their OS daily, which is phagocytized by the RPE, through which they are 
able to remove the toxic byproducts of oxidative metabolism20,21. The importance of 
maintaining normal ROS levels in PRs is further supported by the fact removal of a 
subunit of NADPH oxidase, an enzyme complex that produces ROS, confers protection 
to PRs against light-induced degeneration114. 
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Since rods constitute about 95% of the total PRs, they consume most of the oxygen in the 
outer retina. Therefore once the rods die, the remaining 3-5% of cones are now faced 
with an overload of oxygen105,115,116. The oxidative stress model for secondary cone death 
therefore suggests that the cell number in the PR layer is a critical determinant of cone 
death and may also explain why cone death is a rather slow process in RP, since 
oxidative damage may accumulate over a long period of time and eventually kill cones. 
In this regard, systemic delivery of antioxidants has prolonged cone survival in various 
models of RP104,117. Co-expression of anti-oxidant enzymes such as catalase and 
superoxide dismutase-2 also delayed cone death in the rd10 mouse model of RP118. More 
recently, rAAV-mediated expression of the nuclear factor erythroid derived 2 like 2 
(Nrf2), a transcription factor that regulates various antioxidant enzymes was shown to 
effectively delay cone death in three mouse models of RP119. rAAV-mediated delivery of 
antioxidant enzymes to cone PRs avoids the side effects of globally reducing ROS levels 
that can occur when antioxidants are administered orally or through other systemic 
routes120.  
 
B. Rod-derived cone viability factor: 
Research efforts to determine trophic factors produced by rods led to the identification of 
the rod-derived cone viability factor (RdCVF) in 2004102. This factor is encoded by the 
nucleoredoxin-like 1 gene (NXNL1) and functions as a thioredoxin-like protein.121 Since 
its discovery, various studies have demonstrated its protective effect in mouse models 
either by direct injection as a peptide122 or as a gene therapy123. Consistent with the 
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thioredoxin nature of this factor, retinae of mice lacking the Nxnl1 gene exhibit increased 
oxidative stress and progressive decline in cone and rod function124. Therefore, one could 
speculate that RdCVF protects cones in RP by reducing oxidative stress. However, a 
recent study led to the finding that the mechanism of RdCVF-mediated protection is its 
indirect interaction with glucose transporter-1, which increases glucose uptake in cone-
enriched cultures thereby improving cone cell metabolism.125 This is directly in line with 
our proposed model for secondary cone death, which suggests that cones suffer from a 
glucose shortage upon the loss of rods.  
 
C. Metabolic model of cone death: 
PRs are among the highest energy consuming cells in the human body106. First, they 
utilize large amounts of ATP in order to re-equilibrate membrane potential in response to 
photons of light, as previously discussed. Second, the PR OSs are very densely packed 
with lipids and proteins in order to facilitate the capturing of photons5,6. In fact, the 
average lipid content of a PR cell is about 15%, when compared to about 1% for ‘normal’ 
cells6. Under these circumstances, when a PR cell sheds about 10% of its OS daily, the 
amount of new lipid and protein that needs to be resynthesized every day is 
tremendous126,127. PRs have thus developed elegant mechanisms to enable them to achieve 
their high metabolic demands. PRs derive glucose primarily from the RPE cells and they 
have been shown to take up lactate from Müller Glia cells, with which they are in 
intimate contact in vivo128,129. While glucose is the predominant source of ATP in most 
cells, lactate can also be converted to pyruvate and enter the Kreb’s cycle to fuel ATP 
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synthesis130. Glucose can therefore be utilized in other biosynthetic pathways to generate 
building blocks for membrane synthesis and this is a common feature of cells with a high 
rate of cell division131. Interestingly, there is a study which suggests that most of the 
glucose taken up by PRs does not enter the Kreb’s cycle129, which suggests that similar to 
proliferating cells, PRs may divert most of their glucose for anabolic functions132.  
 
The PR OSs are in intimate contact with the RPE cells and these RPE:OS interactions are 
critical for the transfer of nutrients like glucose from the RPE into PRs. Each RPE cell 
interacts with about 25-30 PR OSs126,133. However, because in humans and mice rods 
outnumber cones at a ratio of 20:1, most of these RPE:OS interactions are those of the 
RPE with rod OSs. Consequently, only one or two cone OSs are in contact with each 
RPE cell. During the initial phases of rod death, these interactions are still intact, 
however as the disease progresses, the massive death of rods causes a disturbance of the 
architecture of the PR layer. This is because rods are much more abundant than cones and 
upon their loss, the PR layer collapses (See Figure 1.4 for illustration). This perturbs the 
interactions of the remaining cone OSs with the RPE, which affects the flow of nutrients 
into cones. Thus, we hypothesized that once a critical ratio of rods to cones is breached 
per RPE cell, cone death initiates as a cell-autonomous event due to a reduction in 
nutrient flow from the RPE. To test this hypothesis, we compared the kinetics of rod and 
cone death across four different mouse models of RP, each of which have a mutation in a 
rod-specific gene that causes the rods to die at different rates13. We observed that 
regardless of the primary mutation in rods, cone death initiates only after about 90% of 
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rods have died. Therefore, the remaining 10% of rods could represent the critical ratio at 
which cone death initiates as a cell autonomous event. The gradual reduction in nutrient 
levels may also explain why cones survival for extended periods of time following death 
of rods.  
 
Figure 1.4: Starvation model for cone death in RP. (A) In a normal retina, rods and cones interact with 
the RPE via their outer segments allowing for transfer of nutrients (depicted as yellow dots). During early 
stages of rod loss, these interactions are still intact (B), however once most rods are lost (C) these collapse 
of the PR layer results in the breaching of the RPE:cone OS interactions (D-E) reducing flow of nutrients 
into cones. Rods are depicted in white, while cones are shown in red-green and blue colors. 
 
Since RPE is the primary source of glucose for PRs, loss of the RPE:cone OS interactions 
are likely to reduce glucose levels in cones and its subsequent divergence into 
biosynthetic pathways like the pentose phosphate pathway (PPP). The PPP generates 
NADPH as a byproduct, which is used as reducing agent for lipid synthesis. The 
shortening of cone OSs that is seen during degeneration may be indicative of a deficit of 
lipids due to insufficient NADPH that is required for their synthesis13,134. Further, 
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NADPH is also required for the regeneration of the visual chromophore necessary for PR 
function. The first step in chromophore recycling is the conversion of all-trans retinal into 
all-trans retinol and requires NADPH as a reducing equivalent19. Thus, the inability to 
efficiently regenerate of the chromophore could explain the reduction in cone function 
during disease. Lastly, NADPH also functions as a reducing agent for glutathione, which 
serves to counteract the effects of oxidative stress135. Therefore, a lack of NADPH is also 
consistent with increased oxidative stress in cones during disease.  
 
In addition to the kinetics of rod and cone degeneration across the four mouse models of 
RP, the following evidences also encouraged us to propose that cones suffer from a 
nutrient shortage13. During cone degeneration, we found an upregulation of the hypoxia-
inducible factor-1 alpha (HIF-1α) and its target gene the glucose transporter-1 (GLUT1). 
HIF-1α is a transcription factor that is normally increased during stress conditions such 
as hypoxia or starvation to improve glycolysis136. Since the loss of rods leads to 
hyperoxic conditions in cones, the increase in HIF-1α is likely to represent a shortage of 
glucose. Our hypothesis was further corroborated by microarray analysis carried out 
across the four mouse models of RP, which revealed an increase in the expression 
metabolic genes at the onset of cone death, particularly genes of the 
insulin/AKT/mammalian target of rapamycin (mTOR) pathway, a key pathway that 
regulates cell metabolism, growth and survival137. Concordantly, we found that cones 
showed increased phosphorylation of the ribosomal protein S6, a bona fide mTOR 
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target137, suggesting that cones were increasing the activity of this pathway, to potentially 
adapt to the shortage of nutrients.  
 
To test whether further activation of the insulin/mTOR pathway would enhance cone 
survival, we treated the rd1 mouse model of RP with daily systemic injections of insulin. 
We found that cone survival did improve, however the therapeutic effect of insulin lasted 
only for a period of four weeks.13 Prolonged treatment with insulin did not result in 
further improved survival, potentially due to the negative feedback loop within the 
insulin/mTOR pathway137, leading to a state of insulin resistance. However, our results 
were encouraging and suggested that activation of pro-growth and/or pro-survival 
mechanisms downstream of the insulin receptor can prolong cone survival. This thesis is 
largely based on studying the events downstream of the insulin receptor that contribute to 
cone survival. We will further elaborate on the insulin/mTOR pathway in the following 
sections.  
 
3. Restoration of visual sensitivity by optogenetics: 
Optogenetics is an emerging field where transmembrane light-sensitive receptors are 
delivered to the eye either to restore visual sensitivity in PRs that have become non-
functional or expressed in non-PR cells such as bipolar or ganglion cells to make them 
photosensitive138. These light receptors are opsin-like proteins such as channel rhodopsins 
and halorhodopsins, which are delivered using rAAV or lentiviral vectors138-141. While 
these proteins are activated in response to light photons, some of them produce an 
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excitatory current while some produce an inhibitory current138. Concordantly, individual 
or combinatorial expression of these proteins have been shown to produce either ON, 
OFF or a combination of the two responses in the inner retinal neurons following death of 
PRs142-145. Expression of halorhodopsin has also successfully restored visual sensitivity of 
dormant cones in mouse models of RP141. The strategy therefore allows for therapeutic 
intervention at late stages of disease. Further, optogenetics can be used to supplement 
approaches that extend PR survival discussed so far, thereby improving their 
functionality.   
 
The large number of approaches as well as disease targets being pursued increase hope 
that there will be therapeutic strategies that will effectively prolong vision in people 
affected by inherited retinal degenerations. A combination of these approaches may be 
more beneficial than a single approach. However regardless of the results obtained in 
animal models, effectiveness in human patients will be the ultimate test for any therapy.  
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Background on the insulin/AKT/mTOR pathway: 
 
 
               
 
Figure 1.5: Schematic of the insulin/AKT/mTOR pathway. The schematic is a simplified version of the 
pathway and is focused on the components that are important to this study. mTOR exists as part of two 
complexes; mTORC1 which regulates pro-growth processes like protein synthesis, glycolysis, lipid 
synthesis and inhibits autophagy, while mTORC2 regulates mainly pro-survival process. Both mTOR 
complexes are activated in response to growth factors, while mTORC1 is also sensitive to amino acids and 
energy levels. See main text for more details on the pathway regulation.  
 
Upon binding of growth factors like insulin, tyrosine kinase (TK) receptors such as the 
insulin receptor phosphorylate and recruit adaptor proteins such as the insulin receptor 
substrate (IRS)146. Phosphorylated IRS proteins in turn facilitate the recruitment of 
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phosphatidylinositol-3-kinase (PI3K) to the plasma membrane, which increases the levels 
of the secondary messenger phosphotidylinositol triphosphate (PIP3) that mediates 
various downstream functions of insulin. The effects of growth factor stimulation are 
counteracted by PTEN (phosphatase and tensin homolog), which converts PIP3 to PIP2, 
thereby reducing downstream signaling events.147   
 
Two key kinases downstream of PIP3 that are central to the insulin/AKT/mTOR pathway 
are protein kinase B (PKB), also known as AKT, and the mammalian target of 
rapamycin, mTOR. AKT has a multitude of targets and 3 isoforms that are often cell-type 
specific148. In contrast, mTOR is found in 2 large protein complexes referred to as 
mTORC1 (mTOR complex 1), which is characterized by the accessory protein Raptor 
(regulatory-associated protein of mTOR) and mTORC2 (mTOR complex 2) 
characterized by the accessory protein Rictor (rapamycin-insensitive companion of 
mTOR)149. The two mTOR complexes possess a distinct set of functions and targets. 
Increased PIP3 levels promote 3-phosphoinositide-dependent protein kinase (PDK1) and 
mTORC2 activity150. In turn, PDK1 and mTORC2 phosphorylate AKT on Thr308 and 
Ser473 respectively. While phosphorylation on both AKT sites is required for full 
activation of AKT, phosphorylation of AKT at Thr308 is sufficient for its activity 
towards mTORC1, and does not require mTORC2-mediated phosphorylation at 
Ser473149. Activated AKT phosphorylates two distinct substrates that lead to activation of 
mTORC1. Phosphorylation of the tuberous sclerosis protein TSC2 known as tuberin, 
relieves the inhibitory effect of the tuberous sclerosis complex (TSC) on mTORC1149,151. 
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The TSC is composed of TSC2 in association with two other proteins, TSC1 (hamartin) 
and TBC1D7 (Tre2-Bub2-Cdc16 (TBC) 1 domain family, member 7), both of which are 
required for complex stability to mediate to downstream effects of the complex152. The 
TSC acts as a GTPase activating protein (GAP) for Rheb (Ras-homolog enriched in the 
brain). In its GTP-bound form, Rheb promotes activation of mTORC1, and its conversion 
to GDP-Rheb by the GAP activity of the TSC complex results in inhibition of 
mTORC1153,154. The second mode of activation of mTORC1 by AKT is through 
phosphorylation of PRAS40 (proline-rich AKT substrate 40kDa). PRAS40 inhibits 
mTORC1 activation by binding to its accessory protein Raptor, and this is relieved by 
AKT-mediated phosphorylation155. Upon mTORC1 activation, the ribosomal protein S6-
kinase (S6K), a target of mTORC1, phosphorylates the IRS and prevents further 
downstream signaling, thereby closing the feedback loop and preventing over-activation 
of the pathway156,157. This is also the feedback loop that we hypothesized was responsible 
for limiting the protective effect of insulin in our studies13. S6K also phosphorylates 
Rictor, the accessory protein of mTORC2, which results in the inhibition of mTORC2 
activity towards its targets such as the serum and glucocorticoid-regulated kinase (SGK) 
and protein kinase C (PKC). However, S6K mediated phosphorylation of mTORC2 does 
not affect its activity towards AKT137,158-161. These feedback loops between mTORC1 and 
mTORC2 as well as between mTORC1 and the IRS allows cells to fine tune mTOR 
activity in response to growth factors and other signals.  
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mTOR complexes: Composition, functions and regulation 
mTOR was identified as the target of rapamycin (also known as Sirolimus), an 
immunosuppressant and antiproliferative agent produced by the bacterium Streptomyces 
hygroscopicus in the Rapa Nui island, hence the name rapamycin162-164. mTOR has a C-
terminal protein kinase domain that is similar to PI3K and thus, belongs to the family of 
PI3K-related protein kinases (PIKK). Other kinases in this family include proteins like 
ATM, ATR and DNA-PK, which are involved in regulating DNA damage and genotoxic 
responses155. In contrast, mTOR is mainly responsible for regulating responses to various 
other stresses such as nutrient, oxygen and energy deprivation.  
 
As mentioned previously, mTOR is found in two distinct complexes, mTORC1 and 
mTORC2 that are characterized by their unique accessory proteins Raptor and Rictor, 
respectively165,166. These accessory proteins are indispensible for complex assembly and 
for the binding of mTOR to substrates and regulatory proteins137. Additionally, the two 
mTOR complexes also contain shared components such as mammalian lethal with 
SEC13 protein 8 (mLST8) and the DEP domain containing mTOR interacting protein 
(DEPTOR) as well as other proteins unique to each complex137,167,168. Rapamycin inhibits 
mTORC1 activity potentially by weakening the interaction of Raptor with mTORC1169. 
However, prolonged exposure to rapamycin has been also shown to reduce mTORC2 
activity in certain systems and this is attributed to the sequestration of the pool of free 
mTOR, thereby reducing mTORC2 complex formation137,170. While both mTOR 
complexes are activated in response to growth factors as described above, mTORC1 is 
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additionally regulated by factors such as energy, nutrient and oxygen levels in cells. 
mTORC1 integrates these inputs and promotes various pro-growth process such as 
protein synthesis, ribosome biogenesis, lipid and mitochondria synthesis and inhibits 
catabolic processes like autophagy. In contrast, little is known about other modes of 
activation of mTORC2, which regulates mainly pro-survival processes137,155.  
 
Activation of mTORC1: 
Nutrients: Amino acids are essential for synthesis of proteins, which are the building 
blocks of the cell. Additionally, amino acids are also required to generate substrates that 
feed into metabolic pathways such as the Kreb’s cycle and hence also required for the 
synthesis of ATP155. mTORC1 is a master regulator of protein synthesis and therefore 
sensitive to the levels of amino acids in the cell. The activation of mTORC1 by amino 
acids is complex and involves various proteins, among which the Rag GTPases are key 
players171,172. These proteins belong to the Rag family of small GTPases and exist on the 
surface of the late endosome and lysosome as heterodimers of either RAGA or RAGB in 
combination with either RAGC or RAGD. Under conditions of sufficient amino acids, 
the Rag heterodimers assume an active conformation, where RAGA/B are bound to GTP, 
while RAGC/D are GDP bound. Under amino acid starvation, the GTP-GDP loading 
states are reversed. In their active conformation, the Rag heterodimers interact with 
Raptor, thereby recruiting mTORC1 to the surface of the lysosome. Therefore under 
conditions of amino acid availability, mTORC1 is localized at the lysosome. This step is 
critical because it facilitates interaction of mTORC1 with Rheb, which also resides on the 
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lysosome and this interaction is critical for the activation of mTORC1171,172. Amino acids 
were also shown to regulate TSC2 localization, where under conditions of amino acid 
starvation, TSC2 is recruited to the lysosome to inhibit Rheb, which consequently inhibits 
mTORC1 activity173. Together, the above studies establish that the lysosome is a critical 
site that integrates both growth factor as well as nutrient inputs to mediate activation of 
mTORC1.  
 
Growth factors: The effect of growth factors such as insulin on activation of mTORC1 
was previously discussed and Rheb, which in its GTP-bound form promotes mTORC1 
kinase activity, is a critical mediator of these effects. Besides promoting phosphorylation 
and inhibition of TSC2 by AKT, growth factor stimulation also results in the dissociation 
of TSC2 from the lysosome, thereby relieving its inhibition on Rheb174. Growth factors 
can also activate mTORC1 through pathways outside of the PI3K-AKT axis. One such 
example is the activation of the Ras pathway by growth factors, which in turn activates 
the extracellular regulated kinase (ERK) that phosphorylates and inhibits TSC2175. 
Additionally, Wnt signaling can also activate mTORC1. Wnt inhibits glycogen synthase 
kinase 3β (GSK3β), which inhibits TSC2 by phosphorylation, thereby activating 
mTORC1176.  
 
Glucose, oxygen and energy levels: Glucose and energy levels are tightly linked because 
the energy from glucose is converted to ATP during glycolysis and oxidative metabolism 
and thus under low glucose conditions, ATP levels decline. mTORC1 detects the 
30
reduction in ATP using a sensor known as the AMP-activated protein kinase (AMPK). 
The levels of AMP and ATP in the cell regulate AMPK allosterically177 and upon low 
ATP levels, AMPK inhibits mTORC1 by two mechanisms. AMPK phosphorylates 
TSC2, stimulating its inhibitory effect on mTORC1178. Besides, it also phosphorylates 
Raptor and promotes its binding with the 14-3-3 proteins, thereby preventing its 
association with mTORC1179. Other than glucose starvation, stress such as hypoxia can 
also lead to an energetic imbalance by impairing mitochondrial metabolism leading to 
AMPK activation137. 
 
Functions of mTORC1: 
Protein synthesis and ribosome biogenesis: Protein synthesis is an energy consuming 
process requiring ATP, GTP as well as synthesis of ribosomal units155. Being a sensor of 
nutrient and energy levels in the cell, it is not surprising that mTORC1 plays a critical 
role in regulating this energy-costly process. Two target proteins are predominantly 
responsible for mediating the effects of mTORC1 namely, S6 kinase (S6K) and eIF4E-
binding protein 1 (4EBP1). eIF4E is the eukaryotic translation initiation factor 4E which 
recruits initiation factors at the 5’ end of most mRNAs, and is inhibited upon binding to 
4EBP1180. This inhibition is relieved upon phosphorylation of 4EBP1 by mTORC1, 
thereby initiating translation181. Phosphorylated S6K promotes mRNA translation by 
phosphorylating proteins such as eIF4B182 and eEF2K183 (eukaryotic elongation factor 2 
kinase). Additionally, S6K is known to increase transcription of rRNA polymerase RNA 
polymerase 1 (RNAP1), which is involved in the synthesis of ribosomal RNAs and 
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proteins184. S6K also phosphorylates S6, which is a component of the 40S ribosome. 
While the role of this phosphorylation remains unclear, it is one of the most commonly 
used readouts of mTORC1 activity137,154. 
 
Metabolism: Gene-expression profiling of cells with constitutively activated mTORC1 
signaling mediated by loss of the TSC revealed that mTORC1 increases the expression of 
various genes involved in glycolysis, lipid synthesis and the PPP185. These effects of 
mTORC1 are mediated by its activation of the sterol regulatory element binding proteins 
(SREBP) and the hypoxia-inducible factors (HIF). SREBP-1 is normally activated in 
response to low sterol and lipid levels and undergoes a processing step, which involves 
cleavage into the active form, which then binds to specific sterol regulatory DNA 
elements186. Activated mTORC1 promotes the posttranslational processing of SREBP-1, 
thereby increasing expression of various genes involved in lipid biosynthesis and the 
PPP185. mTORC1 also increases the translation of HIF-1α, which is known to improve 
glycolysis through increasing expression of enzymes such as hexokinase, 
phosphofructokinase and pyruvate dehydrogenase, besides improving glucose uptake by 
the cell through increased expression of the glucose transporter-1185. Activation of 
mTORC1 is also known to increase mitochondrial biogenesis and oxidative metabolism 
by promoting transcriptional activity of PPARϒ co-activator-1 (PGC1α), a co-activator 
of genes involved in mitochondrial metabolism187. Together, these examples show how 
mTORC1 impinges on various aspects of cell metabolism at the transcriptional, 
translational or post-translational levels.  
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Autophagy and the ubiquitin-proteosome system: Autophagy is a catabolic process by 
which cells degrade cytoplasmic proteins and organelles in lysosomes in order to 
maintain homeostasis, and is especially important for balancing cellular resources under 
conditions of nutrient or energetic stress188. The primary form of autophagy is 
macroautophagy (henceforth, referred to as autophagy) where cytoplasmic cargo is 
delivered to double-membrane organelles called autophagosomes that later fuse with the 
lysosome to form autolysosomes, leading to degradation of its contents189. mTORC1 
functions as a major negative regulator of autophagy and under nutrient replete 
conditions, when mTORC1 is active, it inhibits the initiation of autophagy190. 
Consequently, constitutive activation of mTORC1 in tissues such as skeletal muscle and 
liver leads to accumulation of undigested proteins191-195. Conversely, inhibition of 
mTORC1 by rapamycin or other mTOR inhibitors induces autophagy196. mTORC1 
directly phosphorylates ATG1 (autophagy-related gene 1) also known as ULK1 (unc-51 
like autophagy activating kinase 1), and ATG13 (autophagy-related gene 13) proteins that 
are involved in the formation of the phagophore or the pre-autophagosome, thereby 
inhibiting the process at its inception190,197. Since autophagosomes are known to engulf 
portions of the cytoplasm, autophagy was typically known as a non-selective process198. 
However over the last decade, the identification of autophagy receptors and adaptor 
proteins points towards a great deal of selectivity in the degradation of autophagic 
cargo199,200. We will discuss selective autophagy and other autophagy regulatory 
mechanisms in the following sections.    
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The ubiquitin-proteosome system is involved in the recognition, targeting and 
degradation of ubiquitinated proteins by the proteasome and is the predominant pathway 
for non-lysosomal degradation in the cell201. A recent study showed that mTORC1 
promotes proteosomal degradation by increasing the expression of the master 
transcription factor nuclear factor erythroid-derived 2-related factor 1 (NRF1; also known 
as NFE2L1), which regulates the expression of various proteosomal genes202. The 
increase in proteosomal degradation therefore serves as a resource for cells to maintain a 
constant supply of amino acids in order to keep up with the increased rate of protein 
synthesis that is seen upon activation of mTORC1. Thus, mTORC1 exerts opposing 
effects on the two major degradation systems in the cell, exemplifying its complex 
regulation of cell metabolism and homeostasis.  
 
Functions of mTORC2: 
mTORC2 is known to phosphorylate proteins belonging to the AGC family of kinases 
such as AKT, SGK and PKC through which it exerts its effects on cell survival203-205. 
Additionally, it is known to control proteins involved in the regulation of cytoskeletal 
organization and polarity206,207. While mTORC1 is localized to the lysosome, it is 
suggested that mTORC2 is found at the plasma membrane208, consistent with its role in 
regulating cell polarity as well as phosphorylating AKT following activation by growth 
factors. The phosphorylation of AKT by mTORC2 at Ser473 enhances AKT 
phosphorylation on Thr308 by PDK1, and together they completely activate AKT.137 
34
However, mTORC2-mediated phosphorylation of AKT is not required for its activity 
towards all substrates, as previously stated. For example, AKT-mediated inhibition of 
TSC2 does not require AKT to be phosphorylated at Ser473 by mTORC2. However, loss 
of mTORC2 suppressed the AKT-dependent phosphorylation of the forkhead box 
proteins FOXO1 and FOXO3137,161. The FOXO proteins are transcription factors that 
activate a variety of genes involved in apoptosis and cell cycle arrest209. mTORC2 causes 
exclusion of FOXO from the nucleus210,211 through AKT-mediated phosphorylation of 
FOXO, thereby playing an indirect role in cell survival. However, the FOXO proteins are 
also known to transcribe other autophagy and lysosomal-related genes and therefore, the 
effects of FOXO translocation will have to be assessed based on the cellular context212,213. 
Besides AKT, the SGK family of proteins is also known to regulate FOXO translocation 
as well as the expression of ion channels, thereby also regulating cell size214,215.  
 
The insulin/AKT/mTOR pathway in PRs: 
Given the high-energy demands of PRs, it is surprising that not many studies have 
focused on characterizing the role of this pathway in rods or cones. Loss of the insulin 
receptor, as well as one of the Akt isoforms, Akt2 increases sensitivity to degeneration 
induced by light-stress in rod PRs216,217. With regard to cones, loss of three of five 
regulatory subunits of Pi3k in cones is known to induce cone degeneration218,219. While 
this suggests that PI3K activity is critical for cones, not much is known about the 
signaling events downstream of this kinase that are essential for cone metabolism. This is 
important because it is possible that the protective effects of insulin as well as growth 
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factors such as CNTF were mediated downstream of PI3K. My thesis work stems from 
these gaps in the field and is focused on the characterization of the insulin/mTOR 
pathway in mouse models of RP. Manipulation of cell metabolism generally influences 
autophagy and in our case hopefully also cell death (apoptosis: in particular caspase-2 
mediated) thus we have also explored these aspects during the progression of cone death 
in RP. A brief introduction of these two processes is provided below. 
 
Apoptosis and Caspase-2: 
Apoptosis is a highly regulated form of programmed cell death where a series of 
biochemical events lead to the dismantling of a cell, without leakage of the cellular 
contents to the extracellular space220. Apoptosis is mediated by a family of cysteine 
proteases known as caspases, which can be broadly classified as initiator or executioner 
caspases depending on whether they initiate or partake in the cell death process221,222. 
Caspases are synthesized as pro-caspase zymogens, which are later activated to mediate 
apoptosis. Initiator caspases (examples are caspase-2, -8, and 9) are usually activated by 
proximity-induced oligomerization, aided by adaptor molecules, which bring procaspase 
molecules together, which is followed by autocatalytic processing to yield active caspase 
molecules223. Oligomerization of caspase precursor molecules is however, sufficient to 
activate initiator caspases and the subsequent cleavage only enhances caspase 
activity224,225. Once active, initiator caspases activate executioner caspases (examples are 
caspase-3, -6 and 7) by cleavage, which later mediate cell death by cleaving important 
cellular proteins221. Caspase activity can thus be detected by various methods such as 
36
assessing cleavage of the caspase itself, or cleavage of its target proteins by western blot. 
Other methods include the use of peptides that harbor the amino acid sequence, usually 4-
5 amino acids in length, that is recognized by a specific caspase226. When such a peptide 
is coupled with a fluorescent dye or streptavidin tag, it can be used either for in vivo 
imaging of caspase activity in cells/tissues or for immunoprecipitation experiments.  
 
Caspase-2 has been regarded as the most evolutionarily conserved caspase because it 
shares about 43% amino acid identity with the C.elegans programmed cell death gene 
(CED-3)227. The precursor protein of caspase-2 has three regions; an N-terminal 
prodomain, which contains the CARD motif that facilitates interaction between 
procaspase molecules, followed by a large and small subunit, which together forms the 
catalytic unit of the caspase224. Adaptor proteins such as RAIDD (receptor-interacting 
protein associated CED-3 homologous protein with a death domain) and PIDD (p53 
induced protein with a death domain) bring procaspase molecules together in a complex 
known as the PIDDosome, which facilitates interaction between precursor caspase-2 
molecules, the first step in initiator caspase activation228. This step can be activated by 
stimuli such as heat shock, DNA damage or by mere overexpression of the precursor 
caspase229. This is followed by a series of autocatalytic processing steps resulting in 
removal of the prodomain and cleavage between the large and small subunits resulting in 
a stable heterodimer, which forms the fully active enzyme. However, it should be noted 
that the uncleaved procaspase dimer itself has catalytic activity, albeit to a lesser 
extent224. Once active, caspase-2 functions by cleaving molecules like Bid, a pro-
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apoptotic protein, which disrupts the mitochondrial integrity, thereby releasing molecules 
like cytochrome c and AIF (apoptosis inducing factor) found in the mitochondrial 
intermembrane space230,231. Cytochrome c facilitates activation of other initiator caspases 
like caspase-9, while AIF promotes chromatin condensation and DNA fragmentation. 
Together, these events result in dismantling of the cell.  
 
Metabolic regulation of caspase-2:  
Signaling molecules that sense the existence of metabolites and communicate with the 
cell’s survival machinery are key in deciding the future fate of metabolically 
compromised cells. Several studies have made an elegant connection between 
metabolism and cell fate. For example, low glucose levels result in AMPK-mediated 
phosphorylation of p53 and cell cycle arrest232. This ensures that cell division does not 
progress under conditions of insufficient nutrients. Additionally, glucose levels and/or 
growth factors also regulate various pro- and anti-apoptotic proteins of the Bcl-2 
family233-235 While these events may eventually trigger caspase activation, caspase-2 is the 
only known example where defects in cell metabolism directly result in caspase 
activation. Caspase-2 is activated specifically in response to low NADPH, but not low 
ATP levels, an elegant link that was established in studies performed in oocytes236 
Characterization of Caspase-2-/- mice revealed an increase in number of oocytes in female 
mice, due to which the caspase was thought to play an important role in the elimination 
of excess germ cells during development.237 Later, using the Xenopus laevis system, Nutt 
et al. established that caspase-2 activation was regulated by the metabolic status of the 
38
oocyte, particularly of NADPH, which is synthesized in the PPP236. The authors 
demonstrated that high NADPH levels result in the activation of Ca2+/calmodulin-
dependent protein kinase II (CaMKII), which phosphorylates caspase-2 at Ser135, 
facilitating binding of 14-3-3 proteins to the caspase and preventing its association with 
its adaptor protein RAIDD required for caspase activation236,238. Consequently unhealthy 
oocytes, which do not have sufficient nutrients to increase flux through the PPP to 
generate NADPH, die by a caspase-2 and cytochrome c dependent mechanism. Another 
study also established a link between metabolism and caspase-2 where the authors 
observed that neurons deficient in caspase-2 were more sensitive to nerve growth factor 
(NGF) deprivation237.  
 
Cell death pathways during retinal degeneration:  
Rod cell death in RP has been shown to be predominantly executed by apoptosis and 
involves caspases such as caspase-3 and -7. However, loss of caspase-3 conferred almost 
no protection to rod death in the fast progressing rd1 mouse model239. The redundancy 
among caspases may make it more challenging to inhibit cell death upon removal of a 
single caspase, especially in fast progressing rd1 model. However, in models of 
autosomal dominant RP with slower degeneration kinetics, cell death has been efficiently 
delayed upon removal of caspase-7240 or over-expression of XIAP81. While caspase-3 and 
caspase-7 were thought to have overlapping functions, recent studies suggest that they 
possess unique targets, which may explain the protective effect observed upon caspase-7, 
but not caspase-3 ablation241. On the contrary, the only cell death mechanism described in 
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cones so far is that of necrosis, the inhibition of which delayed early cone death in the 
rd10 mouse model242. Necrosis is a form of cell death that is usually activated in response 
to acute stress and while previously thought to be an uncontrolled form of cell death, 
recent studies show that it also has programmed mechanisms243. The disturbance of the 
retinal architecture from the massive loss of rods is a structural insult to the retinal tissue 
that may induce necrosis in cones. Consequently, administration of necrotic inhibitors or 
loss of RIP3, a key protein in the necrotic pathway conferred protection to early cone 
death242. However besides this finding, there is no study that investigates if cone death 
also involves apoptotic mechanisms. Since our model for cone death suggests that 
glucose and thus NADPH levels are reduced in cones, we investigated if the NADPH-
sensitive Caspase-2 plays a role during cone cell death. The results from this study are 
discussed in Chapter II. 
 
Autophagy: 
While autophagy was briefly introduced, we will now elaborate on this evolutionarily 
conserved process in the context of selective autophagy as well as complex regulation in 
neurons. The autophagy related gene (Atg) proteins constitute the core of the autophagy 
machinery and so far over 30 such proteins have been identified in yeast that are involved 
in various stages of the process from phagophore formation to autophagsosome 
expansion244. A critical step in the expansion of the autophagosome involves conjugation 
of the microtubule-associated protein 1 light chain 3 (LC3 or Atg8, denoted as LC3-I in 
its cytosolic form) to phosphoethanolamine (PE) present in the autophagosome 
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membrane. The LC3-PE conjugate is denoted as LC3-II. Due to the difference in 
molecular weights between LC3-I and LC3-II, the ratio of LC3-II:LC3-I is often assessed 
by western blot as an indicator of autophagic activity189. While autophagy was primarily 
regarded as a bulk, non-selective degradation process, research over the last several years 
indicates a great extent of selectivity in the process. Selectivity is mediated by the 
presence of autophagy receptors and adaptor proteins that are capable of recognizing 
specific types of cargo and interacting with the autophagy core machinery to deliver these 
components for degradation. The autophagy receptors are characterized by the presence 
of a WxxL motif, also known as the LC3-interacting region, which facilitates interaction 
with LC3245-247. p62 was the first autophagy receptor to be identified and remains the most 
well studied receptor till date199. The protein possesses an WxxL motif that allows it to 
interact with the autophagosome, in addition to an ubiquitin-interacting domain that 
facilitates its interaction with proteins/organelles that are marked with ubiquitin for 
degradation200,248. In fact, studies show that p62 is actually required for the formation of 
ubiquitinated aggregates in both dividing cells as well as neurons249,250. However, p62 can 
also recognize cargo that is not ubiquitinated and has been involved in the degradation of 
a wide range of substrates such as bacteria, viral particles in addition to organelles like 
mitochondria, which may or may not be ubiquitinated200. It is important to note that upon 
delivery of cargo to the autophagosomes, p62 also gets recycled and therefore, does not 
accumulate in the cell unless there is a defect in the autophagy process251. Consequently, 
an impairment of autophagy in accompanied by the accumulation of p62 and ubiquitin 
aggregates199. 
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In addition to p62 and few other known autophagy receptor proteins, the autophagy-
linked FYVE protein (ALFY) is a large, scaffold protein that has garnered attention over 
the last few years due to its role in the clearance of ubiquitinated aggregates. This protein 
is also called as WDFY3 due to the presence of WD repeats and FYVE domains. ALFY 
was found to colocalize with p62 and ubiquitin containing aggregates and its structural 
features strongly indicate that it plays a major role in autophagy252. The FYVE domain 
facilitates interaction with PI3P that is found in membranes253, while the WD40 repeats 
are essential for interaction with Atg5254. Additionally, ALFY also possesses PH-BEACH 
(pleckstrin homology-beige and Chediak-Higashi) domains that mediate interaction with 
p62255. Together, these studies reveal that ALFY binds to p62-containing ubiquitinated 
aggregates and links them to the autophagosome through its interaction with Atg5 and 
PI3P. Further, over-expression of ALFY was shown to facilitate clearance of protein 
aggregates in neurodegenerative disease models in vivo, implying a fundamental role for 
this protein in the recognition and targeting of ubiquitinated proteins254.  
 
Regulation of autophagy:  
Under nutrient-rich conditions when mTORC1 activity is increased, autophagy initiation 
is inhibited by mTORC1-mediated phosphorylation of Atg1/ULK1 at Ser757. ULK1 is 
also phosphorylated by AMPK at various sites (Ser555/317/777) and this serves to 
promote autophagy under conditions of energy crisis190,256. It is proposed that mTORC1-
mediated phosphorylation of ULK1 prevents access to AMPK under nutrient-rich 
conditions. Nutrient starvation conditions lead to dissociation of mTORC1 from ULK1, 
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allowing access to AMPK to promote autophagy256. However, these studies were 
performed in dividing cells and a recent study in neurons revealed a rather interesting 
mechanism of autophagy regulation194. The study showed that upon loss of TSC in 
neurons, ULK1 is phosphorylated by mTORC1 at Ser757 as well as by AMPK at Ser555. 
mTORC1 is therefore unable to prevent the association of ULK1 with AMPK, which 
leads to the initiation of autophagy. Therefore unlike dividing cells, neurons with 
constitutive mTORC1 activity maintain an active autophagy flux, suggesting that the 
effects of mTORC1 on autophagy may largely be dependent on the cell type and its 
metabolic demands.  
 
In several systems, the FOXO transcription factors have been shown to be the primary 
regulators of autophagy by transcriptionally increasing expression of genes like LC3 and 
Bnip3 (Bcl-2 19-kDa interacting protein 3), which are required for autophagosome 
maturation. In these studies, mTORC1 activity was dispensable for the induction of 
autophagy212,213. Further, some studies suggest that reduction of amino acids like leucine 
stimulates autophagy in an mTOR-independent manner, although the precise mechanism 
remains unknown257. 
 
mTORC1 and lysosomal regulation: mTORC1 also plays a critical role in the termination 
stages of autophagy and the regulation of lysosomal genes and enzymes. Recently, a role 
for mTORC1 was uncovered in regulating the localization of TFEB (transcription factor 
EB), a transcription factor that promotes expression of various lysosomal genes and 
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enzymes258,259. It was found that under nutrient-rich conditions, mTORC1 phosphorylates 
TFEB at the lysosomal surface and causes its retention in the cytoplasm. Under 
conditions of starvation, when mTORC1 localization at the lysosome is reduced, TFEB is 
not phosphorylated which allows its translocation to the nucleus to regulate expression of 
lysosomal genes. Consequently, inhibition of mTORC1 leads to TFEB translocation to 
the nucleus, while constitutive mTORC1 activation by over-expression of the Rag 
GTPase mutants, leads to retention of TFEB in the cytoplasm. In another study, the 
authors described a phenomenon where prolonged starvation, which induces autophagy 
through suppression of mTORC1, causes a reactivation of mTORC1 signaling over time 
since fusion of the autophagosome with the lysosome release free amino acids, which 
reactivate mTORC1260. This phenomenon known as autophagic lysosome reformation 
(ALR) prevents constitutive autophagy activation, which could have detrimental effects 
on the cell. Further, mTORC1 that is reactivated facilitates the recycling of the lysosomes 
membranes to resynthesize lysosomes, thereby placing a critical role for mTORC1 in 
lysosomal biogenesis and recycling. 
 
Disease models used in the study: 
With this understanding of the complex regulation of the insulin/AKT/mTOR pathway, 
we will now discuss in Chapters II and III, the results obtained upon manipulation of the 
pathway in mouse models of RP. The disease model extensively used in this work is the 
retinal degeneration-1 (rd1) mouse model, which harbors a loss of function mutation in 
the rod-specific phosphodiesterase-6β gene (Pde6b)72. The gene is part of the 
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phototransduction cascade in rods and its deficiency leads to rod death due to an 
accumulation of cGMP within the cell. The rd1 model is one of the fastest progressing 
models of RP, where rod death peaks around P11-P13 and by P21, about 90% of rods 
have died and cone death initiates at this stage.13 We have also employed a second model 
known as the rhodopsin-knockout (Rho-/-) mice, where rod death occurs due to 
incomplete formation of outer segments261. The model displays much slower 
degeneration kinetics, due to which it more closely resembles the progression of disease 
in humans13. However, due to the slower rate of degeneration, one can analyze cone death 
only after 17 weeks of age, which significantly reduces the pace of research. Therefore, 
the rd1 mouse model is more advantageous in this regard since one can investigate the 
effects of manipulating cone death as early as 4-5 weeks of age. While it is challenging to 
prolong cone survival efficiently in this model due to its fast degeneration kinetics, any 
mechanism that protects cones in this model is likely to also function in a slower model.  
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CHAPTER II 
 
mTORC1 activation is both required and sufficient to promote cone survival in 
Retinitis Pigmentosa mice  
  
Introduction: 
The inter-neuronal relationship between rod and cone PRs in humans and mice is that rod 
death always leads to loss of cones, while cone death has only a minimal effect on rods24-
27. This phenomenon plays a central role in RP, since mutations in a few rod-specific 
genes affect disproportionately a large number of patients (RetNet: 
https://sph.uth.edu/retnet/)29. Because cones are essential for daylight, color, and high-
acuity vision, it is their loss that leads to blindness. The fact that cone death always 
follows rod death independently of the underlying mutation in a rod-specific gene 
suggests that the reason(s) for cone death might be similar across various forms of RP. 
Thus, targeting the common mechanism(s) of cone death may allow for the development 
of vision therapies with broad clinical significance.  
 
Previous research in our laboratory comparing the kinetics of rod and cone death across 
four mouse models of RP led to the proposition that cones suffer metabolic imbalances 
following the loss of rods13. Further, at the onset of cone death, we observed gene 
expression changes in many metabolic genes and genes of the insulin/mTOR pathway, a 
key pathway controlling cell metabolism. To test whether activation of the insulin/mTOR 
46
pathway alters cone survival, we treated the fast-progressing rd1 mouse model of RP 
with daily systemic injections of insulin, which activates the pathway13. While cone 
survival did improve, the therapeutic effect of insulin lasted only for a period of 4 weeks, 
possibly due to the negative-feedback loop within the insulin/mTOR pathway (Figure 
2.1). Our findings, though encouraging, left many questions unanswered regarding the 
role of mTOR and its potential as a therapeutic target to promote cone survival in RP. As 
such, it remained unclear whether insulin acts directly on cones to improve cone survival, 
or whether it stimulates other cells such as RPE cells or retinal Müller glia cells to release 
neuroprotective factors, as its administration was systemic. It was also unclear whether 
the protective effect of insulin requires mTOR activity and whether, by circumventing the 
feedback mechanism within the insulin/mTOR pathway, cone survival can be prolonged 
to the point of being therapeutically relevant to humans. Last, it remained to be tested 
whether the effect of insulin can be extended to other mouse models of RP, giving it a 
broader clinical significance.  
 
To evaluate the long-term therapeutic potential of the insulin/mTOR pathway on cone 
survival and to test whether insulin acts directly on cones through this pathway, we have 
now constitutively activated this pathway in cones. Through the use of various 
conditional alleles of genes downstream of the insulin receptor (Figure 2.1, highlighted in 
red) that were deleted using a cone-specific Cre recombinase line262, we uncover a novel 
role for mTORC1 as being required as well as singularly sufficient to promote long-term 
cone survival in RP mice.  
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Figure 2.1: Schematic of the insulin/AKT/mTOR pathway. Conditional knockout alleles that were used 
in the study are denoted in red. A detailed description of the pathway and regulation are found in Chapter I.  
 
Results: 
mTORC1 is required and sufficient to promote cone survival in RP: To evaluate 
whether insulin acts directly on cones through the insulin/mTOR pathway and to test 
whether continued stimulation of the pathway significantly prolongs cone survival, we 
constitutively activated the pathway in cones of rd1 mice by conditional deletion of the 
tumor-suppressor gene phosphatase and tension homolog (Pten) using the Cre-lox 
system263. The Cre driver line used in all our studies is the M-opsin Cre, which uses the 
48
human medium wavelength opsin promoter to achieve cone-specific expression262. This 
Cre driver line has been tested in various studies to achieve deletion of various 
conditional alleles in cones264-266. The rd1 M-opsin-Cre Ptenc/c mice that were generated 
will hereafter be referred to as rd1-PtencKO mice (cKO denotes cone-specific knockout; in 
all instances, Cre+ denotes cKO of the gene indicated). Pten counteracts the action of 
growth factors such as insulin by decreasing intracellular levels of the second messenger 
phosphatidylinositol-trisphosphate (PIP3). Therefore, activation of the pathway by loss of 
Pten is not sensitive to the negative-feedback loop of the insulin/mTOR pathway, as PIP3 
levels remain high even after growth factor receptors are turned off by the feedback 
loop147. As a consequence of sustained pathway activity, we found that cone survival was 
significantly improved in retinae of rd1-PtencKO mice up to 8 months of age when 
compared with cone survival in Cre– littermate control retinae or with that observed in 
retinae following insulin injections in our previous study (Figure 2.2 A and B)13. Cone 
ARRESTIN, a protein that is enriched in cones was used as a proxy to evaluate cone 
survival. The surface area of the retina that is covered by cone arrestin signal was first 
calculated and then extrapolated to percentage of cone survival. This method provides an 
unbiased, accurate estimation of cone survival during disease and is described in detail in 
Chapter V. All cone survival quantification data are representative of at least 8 retinae per 
genotype, unless specified.  
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Figure 2.2: Loss of Pten promotes cone survival in rd1 mice. Data shown are from rd1-mutant mice 
harboring the Ptenc/c allele. (A) Representative retinal flat mounts of rd1-mutant mice at 2 months of age 
showing more central cones in Cre+ animals (red signal indicates cone arrestin). Scale bar: 1 mm (left); 
200μm (right). (B) Quantification of cone survival at the indicated time points. **P < 0.01 and ***P < 
0.005 by Student’s t test. (C) Immunofluorescence analyses at P21 of retinal flat mounts to detect 
phosphorylation of sites on the indicated proteins (red signal). Upper right of each panel shows 
magnification of the area indicated by an arrow. Cone layer is identified by PNA staining (green signal 
indicates PNA; blue signal indicates nuclear DAPI). Scale bars: 20μm (magnifiction for insets, 2.5X 
original). 
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The improved cone survival obtained upon loss of Pten suggests that sustained cell-
autonomous activation of the pathway in cones can serve as a long-term therapeutic 
strategy to prolong cone survival in RP. 
Loss of Pten activates various downstream signaling pathways and kinases; however two 
key kinases downstream of PTEN that are central to the insulin/mTOR pathway are 
mTOR, which exists in two complexes, and AKT137,149. To identify which kinase(s) 
downstream of PTEN promote(s) cone survival, we first assessed the phosphorylation 
status of AKT and other bona fide targets of both mTOR complexes. 
Immunofluorescence on retinal flat mounts at P21 revealed an increase in the number of 
cones positive for PDK1 dependent phosphorylation of AKT at Thr308 and a decrease in 
the number of cones positive for mTORC2-mediated phosphorylation of AKT at Ser473. 
Consistent with this finding, the number of cones positive for phosphorylated SGK-1, 
another mTORC2 target, was also reduced, while the number of cones phosphorylated on 
ribosomal protein S6 (p-S6), an indirect mTORC1 target, was increased (Figure 2.1 C). 
Since phosphorylation of AKT on both sites is required for most AKT-mediated 
prosurvival functions, but phosphorylation on Thr308 is sufficient to activate mTORC1, 
the data suggest that cone survival upon loss of PTEN is mediated mainly by increased 
mTORC1 activity149,161. The reduction in mTORC2 activity upon loss of PTEN is likely 
due to the inhibitory effect of mTORC1 on mTORC2158,160. 
We were not able to detect any of the above phosphorylation changes by western blot on 
whole retinal extracts (Figure 2.3 A). This result could be explained by the low 
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proportion of cones in the retina (3%)2 and/or the high expression levels of these 
phosphorylated proteins in other retinal cell types (Figure 2.3 B), which makes it difficult 
to detect cone-specific changes in whole retinal extracts. Therefore, immunofluorescence 
analyses on whole retinal mounts or sections will be the preferred method of detection of 
cone-specific changes. 
                 
Figure 2.3: Challenges in detecting cone–specific changes by western blot. (A) Western blot analyses 
from whole retinal extracts at P21 from Ptenc/c mice in the rd1 background. Proteins of interest are 
indicated on the right. (B) Immunofluorescence analysis at P21 on retinal cyrosections of Ptenc/c mice for 
phosphorylation on sites of proteins indicated (red signal). Arrows show possible low level of expression or 
background noise of phospho (p) AKT473 and SGK422 in PRs, while pAKT308 and pS6240 appear almost 
undetectable in PRs. In contrast, robust expression is seen in the inner nuclear layer (INL) and/or ganglion 
cell layer (GCL). This makes it difficult to detect phosphorylation changes of these proteins by western blot 
using whole retinal extracts as Pten is lost only in cones. Additionally, after the loss of most rods, retinal 
extracts contain mainly proteins of INL and GCL cells (green: PNA; magenta: short-wave opsin; blue: 
nuclear DAPI; IS: inner segment; ONL: outer nuclear layer; OS: outer segment). Scale bar: 50μm. 
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To test whether increased mTORC1 activity is responsible for the survival effect 
mediated by loss of Pten, we generated rd1 mice with simultaneous deletion of Pten and 
Raptor (Raptorc/c allele267) in cones (rd1 M-opsin-Cre Ptenc/cRaptorc/c) and quantified 
cone survival in these mice at 2 months of age, a time point at which the difference in 
cone survival was quite large following loss of Pten. Interestingly, concurrent loss of 
Pten and Raptor not only abolished the survival effect seen upon loss of Pten, but also 
accelerated cone death (Figure 2.4 A and B). A similar acceleration of cone death was 
seen upon loss of Raptor alone, while loss of Rictor (Rictorc/c allele267) in cones had no 
effect on cone survival in rd1 mice (Figure 2.4 A and B). Loss of Raptor and Rictor was 
verified by phosphorylation changes in their downstream targets S6, AKT, and SGK1 
(Figure 2.4 C). The results show that mTORC1 activity is not only required for the 
improved cone survival seen upon loss of Pten, but is also critical for cone survival under 
the stress conditions encountered during disease. Furthermore, the data suggest that 
known mTORC2- and AKT-mediated prosurvival mechanisms do not contribute to cone 
survival upon loss of Pten. 
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Figure 2.4: Raptor but not Rictor is required for loss of Pten-mediated survival. Data shown are from 
rd1-mutant mice harboring the indicated conditional alleles. (A and B) Representative retinal flat mounts 
(A) and quantification of cone survival (B) at 2 months of age (red signal indicates cone arrestin). ***P < 
0.005 by Student’s t test. (C) Immunofluorescence analyses (red signal) of retinal flat mounts at P21 to 
detect phospho-specific sites on the indicated proteins (green signal indicates PNA; blue signal indicates 
nuclear DAPI). 
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It is important to note that while loss of Raptor accelerated cone death in rd1 mice, 
neither loss of Raptor nor Rictor had any effect on cone survival of wild type mice 
(Figure 2.5) suggesting that mTOR activity is not required to keep cones alive in a wild 
type background.  
                                                 
 
Figure 2.5: Neither loss of Raptor nor Rictor affects cone survival in wild type mice. 
Immunofluorescence analysis on retinal cryosections from mice harboring either the Raptorc/c or Rictorc/c 
conditional allele showing normal distribution of cones. (Red signal: cone arrestin; green: CRE 
recombinase; blue: nuclear DAPI) CRE and cone-arrestin staining are shown separately below in grayscale 
for Cre+ mice. 
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To corroborate whether increasing mTORC1 activity alone is sufficient to prolong cone 
survival, we disrupted the tuberous sclerosis complex (TSC) by ablation of Tsc1, which 
results in robust and constitutive activation of mTORC1. This was achieved by using 
mice with conditional allele for Tsc1 to disrupt the TSC in cones of rd1-mutant mice (rd1 
M-opsin-Cre Tsc1c/c mice268, herein referred to as rd1-Tsc1cKO). At 2 months of age, loss 
of Tsc1 in these mice resulted in a more pronounced rescue of cones when compared with 
loss of Pten. Many of the retinae displayed almost wild type distribution of cones in 
central areas. The protective effect was significant up to 8 months of age (Figure 2.6 A 
and B). Cone function in these mice at 2 months of age, as evaluated by full-field 
electroretinography (ERG), was maintained at the levels recorded at the onset of cone 
death (P21), while it declined in Cre– animals (Figure 2.6 C). ERG recordings are low in 
the rd1 mutant at the onset of cone death when compared with those in WT mice (~20% 
of WT), because rod degeneration starts before eye opening and before outer segments 
(OSs) have fully matured104,269,270. When compared with loss of Pten, S6 was uniformly 
phosphorylated in cones, demonstrating a robust activation of mTORC1 in rd1 Tsc1cKO 
retinae (Figure 2.6 D). 
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Figure 2.6: Activation of mTORC1 promotes cone survival and maintains cone function in rd1-
mutant mice. (A–D) rd1-mutant mice harboring the Tsc1c/c allele. (A) Representative retinal flat mounts 
from rd1-mutant mice at 2 months of age showing a higher concentration of central cones in Cre+ animals 
(red signal indicates cone arrestin). Scale bars: 1 mm (left); 200 μm (right). (B) Quantification of cone 
survival at the indicated time points. *P < 0.05 and ***P < 0.005 by Student’s t test. (C) Evaluation of 
cone function by photopic ERG recordings in mice at P21 and 2 months of age showing b-wave amplitude, 
the average response time of the b-wave peak, and representative recordings in animals at 2 months of age 
(left to right). The same ERG protocol was used for WT and rd1 animals. The data are representative of 
recordings in at least 5 animals per genotype. ***P < 0.005 by Student’s t test. (D) Immunofluorescence 
analyses to detect p-S6 on 2 different mTORC1-dependent sites (red signal) at P21 (green indicates PNA; 
blue indicates nuclear DAPI). Scale bar: 20 μm (magnification for insets, 2.5X original). 
  
57
                                      
Figure 2.7: mTORC1 is sufficient to prolong cone survival in RP. (A–C) Data shown are from mice on 
an rd1-mutant background harboring the indicated conditional alleles. (A) Representative retinal flat 
mounts from mice at 2 months of age (red signal indicates cone arrestin). Scale bar: 1 mm. (B) 
Quantification of cone survival in mice at 2 months of age. *P < 0.05 and ***P < 0.005 by Student’s t test. 
(C) Immunofluorescence analyses of retinal flat mounts to detect pS6 at P21. pS6 was absent from the cone 
layer (green signal indicates PNA) upon loss of Tsc1 and Raptor, while the number of cones positive for 
pS6 increased upon loss of Tsc1 and Rictor (blue signal indicates nuclear DAPI). Scale bar: 20μm.  
(D and E) Ki67 staining (red signal) in retinae of rd1 Tsc1cKO mice at 2 months of age (D) and WT mice at 
P0 (E), when cell division is ongoing (green signal indicates PNA; blue signal indicates nuclear DAPI). 
Higher magnification (30X) is shown on the right side of each panel. Scale bar: 20 μm. 
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Loss of the protective effect by simultaneous ablation of Tsc1 and Raptor, but not Tsc1 
and Rictor, confirmed that mTORC1 activity was both required and sufficient to promote 
cone survival (Figures 2.7 A-C). Importantly, while mutations in TSC cause benign 
tumors in tissues such as the kidney and brain271, loss of Tsc1 in cones did not induce 
cone proliferation as assessed by the proliferation marker Ki67, indicating that the 
protection was due to improved cone survival and not cone numbers (Figures 2.7 D and 
E). 
 
mTORC1 prolongs cone survival by improving cell metabolism: As discussed in 
Chapter I, PRs are among the most metabolically active cells in the human body, since 
they need to replenish membranes and proteins lost due to the daily shedding of their 
OSs106,272. Consequently, PRs require large quantities of glucose to synthesize sufficient 
amounts of NADPH to keep up with daily membrane synthesis. mTORC1 is at the center 
of cell growth and proliferation, regulating genes involved in glycolysis, the PPP, and de 
novo lipid synthesis185. We therefore investigated whether sustained mTORC1 activity 
increases the expression of key metabolic target genes that increase NADPH production 
in cones, thereby improving survival and function. As such, we analyzed the expression 
of glucose transporter 1 (GLUT1), which increases glucose uptake, hexokinase-II (HKII), 
which phosphorylates glucose more effectively, and glucose-6-phosphate dehydrogenase 
(G6PD), which shunts glucose into the PPP for NADPH synthesis273. 
Immunofluorescence analysis revealed an increase in the expression of all 3 
aforementioned genes in cones of 2-month-old rd1 Tsc1cKO mice (Figure 2.8 A). We did 
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not observe this increase in immunofluorescence upon the concurrent loss of Tsc1 and 
Raptor (Figure 2.8 A), indicating that the increase was mTORC1 dependent.  
 
 
Figure 2.8: mTORC1 activation improves glucose metabolism in cones. (A) Immunofluorescence 
analyses to detect the indicated proteins (red signal) on retinal flat mounts from 2-month-old rd1 mice 
harboring the indicated conditional alleles. Concurrent loss of Tsc1 and Raptor abolished the increase in 
immunoreactivity seen upon loss of Tsc1 alone (green signal indicates PNA; blue signal indicates nuclear 
DAPI). Scale bar: 20 μm. (B) NADPH measurements on whole retinal extracts at P21 from Tsc1c/c mice in 
rd1-mutant and WT backgrounds (ng/retina, nanogram per retina). *P < 0.05 by Student’s t est. Data are 
representative of 3 biological replicas, with 3 retinae per replica. (C) Representative images of outer 
segments (OS) from WT (top panel) and rd1 Tsc1c/c mice (middle and bottom panels) at 2 months of age. 
(D) Quantification of OS length and width at the indicated time points. ***P < 0.005 by Student’s t test. 
Data represent 40 measurements performed on 2 animals in each genotype.  
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Figure 2.9: Increase in expression of metabolic genes upon loss of Tsc1 during disease. 
Immunofluorescence analysis for proteins indicated (red signal) on retinal cryosections from rd1 mice 
harboring the Tsc1c/c allele at 2 months of age. Dotted lines depict the border between the cone layer and 
the INL. In rd1 mice all 6 proteins are expressed at higher levels in the cone layer upon loss of Tsc1 (see 
also Figure 2.8 for immunofluorescence analysis on flat mounts for GLUT1, HKII and G6PD). Arrows 
show expression of glucose transporter-1 (GLUT1) on cone membrane, while double and triple arrowheads 
show expression on the apical and basal side of the RPE respectively (green: PNA; blue: nuclear DAPI, 
INL: inner nuclear layer, GCL: ganglion cell layer) 
 
The increase in expression of GLUT1, HKII and G6PD in rd1-Tsc1cKO cones suggests 
that glucose uptake, retention, and divergence to the PPP are improved. Other glycolytic 
genes that contribute to an increase in NADPH production, such as pyruvate kinase 
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muscle isoform 2 (PKM2) and malic enzyme 1 (ME1), were also seen by 
immunofluorescence to be upregulated in cones of rd1 Tsc1cKO mice at 2 months of age, 
as was an increase in the transcription factor hypoxia-inducible factor 1 α (HIF-1α), 
which regulates the transcription of many glycolytic genes (Figure 2.9)185,274 
 
In agreement with these findings, we detected significantly higher levels of NADPH in 
whole retinal extracts from rd1 Tsc1cKO mice at P21 (Figure 2.8 B), a time point at which 
cone death initiates but at which cone distribution was still similar between Cre– and Cre+ 
littermate controls. The cone death kinetics upon Tsc1 loss from P21 to 2 months of age 
is represented later in Figure 2.11. Interestingly at this time-point, among the 
aforementioned metabolic genes, immunofluorescence showed that only ME1 expression 
was increased at P21 (Figure 2.10 A). This suggests that while mTORC1 signaling is 
active at P21 (Figure 2.6 D), the expression of these metabolic genes increases gradually 
over time. To further test this finding, we performed quantitative RT-PCR (qRT-PCR) 
analysis at P21 and P24 and found that most metabolic genes started to display a modest 
but statistically significant difference between Cre– and Cre+ retinae by P24 (Figure 
2.10B) 
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Figure 2.10: Increased expression of mTORC1 targets over time. (A-C) Immunofluorescence analysis 
on retinal flat mounts (A) and quantitative real-time polymerase chain reaction (qRT-PCR) (B, C) on rd1 
mutant mice harboring the Tsc1c/c allele. (A) Immunofluorescence analyses at P21 for proteins indicated 
(red signal). Apart from ME1, none of the other genes showed a clear increase in expression upon loss of 
Tsc1 at P21 when compared to 2 months (Figure 2.8A and 2.9) (green: PNA; blue: nuclear DAPI). Scale 
bar: 20μm. (B, C) qRT-PCR analysis for genes indicated on cDNA synthesized from retinal extracts at P21 
(B) or P24 (C). Error bars: SD. P-values: ***<0.005; **<0.01; *<0.05; ns: not significant, calculated by t-
Test. Data represents average of 3 biological samples run in duplicates with two animals per sample (HKI: 
hexokinase I; 6PGD: 6-phosphogluconate dehydrogenase). 
 
Performing the qRT-PCR or NADPH assay at a later time point would have complicated 
the interpretation of the data, as the differences in cone density between Cre– and Cre+ 
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retinae becomes statistically significant after P24 (Figure 2.11), and thus any difference 
could be attributed to the greater number of cones.  
                    
Figure 2.11: Early cone death kinetics. (A) Quantification of cone survival in rd1 mice harboring the 
Tsc1c/c allele at time points indicated. P-values: ***<0.005; ns: not significant, calculated by t-Test. (B) 
Western blot for cone-arrestin from whole retinal extracts at time points indicated (Lanes separated by 
vertical lines of the time point P24 were run on a separate gel and inserted into the figure). 
 
In agreement with an improvement in NADPH synthesis as well as a progressive increase 
in metabolic gene expression, we found that OS length was maintained in Cre+ mouse 
retinae between P21 and 2 months of age (Figure 2.8 C and D). Since NADPH is also 
essential for chromophore recycling19, its increase, in conjunction with maintained OS 
length and a higher number of cones, may account for the higher ERG recordings in Cre+ 
animals at 2 months of age (Figure 2.6 C). 
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Interestingly, we did not detect any significant increase in NADPH in retinal extracts 
from WT mice in which Tsc1 was ablated in cones by the same Cre driver line (Figure 
2.6 B). This is consistent with the finding that loss of Tsc1 did not cause an increase in 
the expression of any of these genes in the cones of WT mice by 2 months of age (Figure 
2.12, only GLUT1 and HIF-1α are depicted, however no difference was observed in any 
of the other metabolic genes), which suggests that mTORC1 only regulates the 
expression of these genes under disease conditions.  
                                    
Figure 2.12: Loss of Tsc1 induces expression of metabolic genes only under disease conditions. 
Immunofluorescence analysis for proteins indicated (red signal) on retinal cryosections from mice 
harboring the Tsc1c/c allele at 2 months of age. Compared to rd1 mice (Figure 2.9), none of the metabolic 
genes show an increase upon loss of TSC1. (Green: PNA; blue: nuclear DAPI; 3/5 of DAPI signal has been 
removed to visualize the expression of the protein indicated to the right) ONL: outer nuclear layer, INL: 
inner nuclear layer, GCL: ganglion cell layer 
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In summary, sustained activation of mTORC1 in cones improves cone survival and 
function under disease conditions by gradually increasing the expression of genes 
involved in glucose uptake, retention, and utilization. 
To further test whether NADPH levels are crucial for cone survival during disease, we 
examined the role of the initiator caspase, caspase-2 (CASP2), a protease that initiates 
apoptotic cell death and has been shown to be activated under low intracellular NADPH 
levels but not low ATP levels236. Caspases are commonly activated by cleavage, thus the 
identification of a cleavage product is generally used to assess caspase activity275. 
Western blot analysis using retinal extracts from rd1 mice revealed no cleaved CASP2 
products, while cleaved CASP2 was readily detectable after transfection of HEK239 cells 
with full-length Casp2 (Figure 2.13 A), suggesting that CASP2 is not cleaved during 
cone degeneration. However, because dimerization of initiator caspases is sufficient to 
activate the protease, albeit to a lesser extent, the absence of a cleavage product does not 
necessarily mean that a caspase is not active224. To further test whether CASP2 was 
activated in cones, we performed immunofluorescence analyses using 6 different CASP2 
antibodies, none of which revealed any specific pattern of loss of CASP2 expression in 
the retinae of Casp2–/– mice, making it difficult to determine whether CASP2 was 
actually expressed and activated in cones (data not shown). However, Western blot 
analyses using extracts of the photoreceptor-enriched retinoblastoma cell line Y79 
revealed an immunoreactive band (Figure 2.13 A), suggesting that CASP2 may be 
present in photoreceptors.  
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Figure 2.13: Loss of Casp2 slows cone death. (A) Western blot analyses of full-length and cleaved 
CASP2 with retinal extracts of indicated genotypes (left) and with cell culture extracts (right) of HEK293 
cells, HEK293 cells transfected with full-length Casp2, and extracts of the photoreceptor-enriched 
retinoblastoma cell line Y79. (B) Immunofluorescence to detect active CASP2 (green signal indicates 
FITC-labeled CASP2 activity peptide) and red-green opsin (red signal) in retinae of 2-month-old rd1 
animals. Top row, left to right: Retinal flat mount showing the CASP2-active zone (between the dotted 
lines) of cell death progressing toward the periphery. Middle panel: No CASP2 activity was detected in the 
absence of Casp2. Right panel: Higher magnification of central-to-peripheral death wave is demarked by 
the dotted line. To the left of the line, little CASP2 activity was seen, and many cells still expressed red-
green opsin (red signal), while to the right of the line, there were few red-green opsin–positive cells and 
many cells positive for activated CASP2. Bottom panels: higher magnification showing that cells with 
more CASP2 activity (arrowheads) had pyknotic nuclei and less red-green opsin immunoreactivity as 
opposed to cells with more red-green opsin immunoreactivity (arrows; blue signal indicates nuclear DAPI).  
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(C) Representative retinal flat mounts from mice of the indicated genotypes at 10 and 20 weeks of age. (D) 
Quantification of cone survival in rd1 and Casp2–/– rd1 mice at the indicated time points. *P < 0.05 by 
Student’s t test. (E) Immunofluorescence analyses to detect cone arrestin (red signal) and PNA (green 
signal; blue signal indicates nuclear DAPI) in retinal cryosections from 20-week-old WT and Casp2–/– 
mice. 
To determine whether CASP2 was activated in cones without cleavage, we used a peptide 
bearing the CASP2 target sequence (VDVAD) conjugated with the fluorophore FITC. 
The peptide becomes covalently linked once bound to the active site of the protease, 
facilitating the clearance of unbound excess peptide. Using this assay, we found that 
CASP2 activity occurred mainly in cones that lacked red-green opsin expression and 
displayed pyknotic nuclei, a key characteristic of apoptotic cells (Figure 2.13 B). 
Moreover, the pattern of cells positive for CASP2 activity reflected the central-to-
peripheral progression of cone death, suggesting that we were indeed capturing dying 
cones across the retina. However, because the sequence of caspase-binding peptides is 
rather short, false-positives can occur. To test for specificity of the activity assay and to 
determine whether Casp2 plays a role in vivo during cone degeneration, we crossed the 
Casp2–/– allele onto an rd1-mutant background (Casp2–/– rd1). Loss of CASP2 not only 
abolished any CASP2 activity seen in rd1 retinae (Figure 2.13 B), but also significantly 
improved cone survival in the retinae of these mice at 20 weeks of age (Figure 2.13 C and 
D), while loss of CASP2 in WT mice did not affect PR survival (Figure 2.13 E). In 
summary, the data suggest that removal of an NADPH-sensitive cell death mechanism 
can delay cone death in RP, further supporting the notion that cone death in RP is 
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intimately linked to glucose and NADPH levels and indicating that cone death is likely a 
result of nutrient deprivation. 
 
     
Figure 2.14: Cone protection mediated by loss of Tsc1 is conserved in RP. Data shown are from Rho–/– 
mice harboring the Tsc1c/c allele. (A) Representative retinal flat mounts from mice at 30 weeks of age (red 
signal indicates cone arrestin). Scale bar: 1 mm. (B) Quantification of cone survival in mice at 30 weeks of 
age. ***P < 0.005 by Student’s t test. (C) Immunofluorescence analyses to detect the indicated proteins 
(red signal) on retinal flat mounts (green signal indicates PNA; blue signal indicates nuclear DAPI). Scale 
bar: 20 μm. 
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Constitutively activated mTORC1 delays cone death in rhodopsin-KO mice: To test 
whether improved cone survival mediated by increased mTORC1 activity is applicable to 
other models of RP, we used the rhodopsin-KO (Rho–/–) mouse261, which displays slower 
degeneration kinetics. Cone death initiates at around 17 weeks of age, and by 30 weeks of 
age, Rho–/– retinae show a degree of cone degeneration equivalent to that of 2-month-old 
rd1 mouse retinae. Similar to the observations made in the rd1 mouse model, loss of Tsc1 
in the cones of Rho–/– mice was able to significantly prolong cone survival at 30 weeks of 
age (Figure 2.14 A and B). Moreover, increased immunoreactivity against metabolic 
genes such as HKII and PKM2 in cones, as well as an increase in the number of cones 
positive for p-S6 (Figure 2.13 C), indicates that the mechanism of protection is similar to 
that observed in rd1 cones. These findings suggest that this approach is independent of 
the mutation in a rod-specific gene, allowing for therapeutic intervention at the mTORC1 
level to prolong vision in RP. 
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CHAPTER III 
 
 
 
mTORC1 activation that maintains autophagy is more beneficial for long-term cone 
survival of RP mice 
 
 
 
Introduction: 
 
In Chapter II we demonstrated that constitutive activation of the mammalian target of 
rapamycin complex 1 (mTORC1), mediated by loss of either of the two negative 
regulators, Pten or Tsc1, promoted cone survival for a period of up to 8 months in rd1 
mice (Figures 2.2 and 2.5). Because Tsc1 is a direct upstream negative regulator of 
mTORC1, its removal promoted a more robust rescue of cones at 2 months of age, with 
many retinae displaying almost a wild type distribution of cones. The protective effect of 
mTORC1 activation was conserved in two mouse models of RP and promoted survival of 
nutrient stressed cones by improving glucose uptake and utilization. However, while cone 
protection remained initially stable, cone loss eventually resumed beyond 2 months of 
age. Since activation of mTORC1 affords a mutation independent approach to prolong 
vision, we investigated why in rd1 mice with loss of Tsc1, cone death resumed between 
2-4 months of age. mTORC1 is a critical negative regulator of autophagy and to study if 
loss of Tsc1 in rd1 cones, while promoting cone survival through strong activation of 
mTORC1, may have simultaneously introduced an unwarranted secondary problem, we 
analyzed the process of autophagy at 2 months of age, a time point just prior to when 
cone death resumes upon loss of Tsc1.  
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We show that loss of Tsc1 in cones causes a defect in autophagy leading to an 
accumulation of autophagic aggregates in both wild type and rd1 mice. We demonstrate 
that this defect was not due to an inhibition of autophagy initiation, but due to an 
accumulation of autolysosomes, suggesting a defect in the end-stage of the process. The 
incomplete digestion of proteins caused an amino acid shortage in cones thereby 
hampering long-term cone survival. To facilitate autophagy, we administered the 
allosteric mTORC1 inhibitor rapamycin, which enhanced survival of cones with Tsc1 
loss at 4 months of age. Interestingly, improved cone survival did not depend on the 
clearance of autophagic aggregates, rather on maintaining autophagy at a steady state. In 
this regard, we found that moderate activation of mTORC1 by loss Pten, while initially 
less efficient at promoting cone survival, maintained autophagy and protected cones for 
up to 1 year, when the protective effect by Tsc1 removal was lost. This suggests that 
therapeutic interventions with mild mTORC1 activators that maintain autophagy or gene 
therapy with selected mTORC1 targets are achievable objectives to delay vision loss in 
patients with RP. 
 
Results: 
Impaired autophagy upon loss of Tsc1 in wild type mice leads to a progressive 
decline in cone function and cone specific proteins. To study the long-term effect of 
Tsc1 loss in cones of mice with retinal degeneration (rd1-Tsc1cKO mice) we first analyzed 
the effect of its loss in wild type mice (Tsc1cKO mice). In Chapter II, we demonstrated that 
Tsc1cKO mice did not show an increase in metabolic gene expression in cones by 2 months 
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of age (Figure 2.12) however; we did not further characterize its effect on cone function 
and survival. Electroretinogram (ERG) recordings on mice with Tsc1 loss showed a 
strong reduction in cone function over a period of one year with a statistically significant 
decline as early as 3 months of age (Figures 3.1 A and B). In agreement with the decline 
in cone function, a cone count, using an antibody directed against the cone specific 
protein cone ARRESTIN, showed significant loss of cone-arrestin positive cones over-
time (Figure 3.1 C). To count cones, retinae were divided into two sectors of radii 1mm 
and 2mm respectively, and cones were manually counted in four squares per sector, each 
square measuring 40,000 µm2. More details about cone quantification are provided in 
Chapter V.  
 
mTORC1 is a critical negative regulator of autophagy and impaired autophagy due to 
constitutive activation of mTORC1 has been shown to affect cellular function and 
survival in various tissues191,192,194. We therefore examined the status of autophagy in 
cones of Tsc1cKO mice, by evaluating the expression of p62, an adaptor protein that is 
involved in the recognition and targeting of autophagic cargo, such as ubiquitinated 
proteins, to the lysosome for degradation276. We observed an accumulation of both p62 
and ubiquitin in cones of Tsc1cKO mice, suggesting a defect in the clearance of 
ubiquitinated proteins (Figure 3.1 D and E). Taken together, our observations suggest that 
loss of Tsc1 in cones leads to a defect in autophagy, which could in part, be responsible 
for the decline in cone function and associated loss in cone specific proteins.  
                         
73
                          
Figure 3.1: Loss of Tsc1 in cones of wild type mice leads to defective autophagy and progressive 
decline of cone function. Data shown are from mice harboring the Tsc1c/c allele. (A-B) Evaluation of cone 
function over time showing average b-wave amplitudes (left) and representative photopic ERG traces 
(right) at indicated time points. Data are representative of recordings from at least 6 mice per genotype.  
*P < 0.05, ***P < 0.001, ****P < 0.0001 by Student’s t test. (C-D) Evaluation of cone survival: Bar graphs 
representing the average number of cone arrestin positive cones/mm2 in Sector 1 & 2 over a period of 1 
year. Data are representative of at least 2 mice in each group. *P < 0.05, **P < 0.01 by Student’s t test.   
(D-E) Immunofluorescence analysis on retinal whole mounts of p62 and UBIQUITIN (red signal) at 2 
months of age. Cones are marked in green by PNA. Scale bars: 20μm 
 
74
Loss of Tsc1 in cones of RP mice causes an accumulation of autolysosomes. The 
findings in wild type mice led us to assess if loss of Tsc1 also impairs autophagy in RP 
mice (rd1-Tsc1cKO) where cones are subject to conditions of nutrient deprivation. Similar 
to our observations in wild type mice, rd1-Tsc1cKO mice showed an accumulation of p62 
and ubiquitin aggregates in cones (Figure 3.2 A). The prevalent model for mTORC1-
mediated inhibition of autophagy is through its direct phosphorylation of ULK1 (Unc-51 
like autophagy activating kinase-1) at Ser757, a protein that forms part of the autophagy 
initiation complex190. To test if loss of Tsc1 did indeed inhibit autophagy initiation we 
injected Cre- and Cre+ rd1-Tsc1c/c littermates subretinally at birth with a recombinant 
adeno-associated virus (rAAV9) that expresses a tandem-tagged mCherry-GFP-LC3 
gene189. LC3 (Microtubule-associated protein 1 light chain 3) is part of the 
autophagosomal membrane and remains associated with it even after fusion with the 
lysosome189. Therefore, besides assessing for autophagy initiation, the vector also allows 
monitoring autophagic flux since the GFP portion of the LC3 reporter construct is pH 
sensitive. Consequently, autophagosomes appear yellow expressing both red and green 
fluorescence (mCherry+/GFP+), while autolysosomes appear only red (mCherry+/GFP−) as 
GFP is quenched by the low pH of the autolysosome. At 2 months of age we found a 
significant increase in the number of autolysosomes in rd1-Tsc1cKO cones (Figure 3.2 B 
and C), while the number of autophagosomes was similar between Cre- and Cre+ 
littermates. The data also point towards the existence of an active autophagy flux in rd1-
Tsc1cKO cones.   
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Figure 3.2: Tsc1 loss maintains autophagic flux in cones of rd1 mice and causes an increase in 
autolysosomes. Data shown are from rd1 mutant mice harboring the Tsc1c/c allele at 2 months of age. (A) 
Immunofluorescence analyses on retinal flat mounts for proteins indicated (red signal). Cone layer was 
identified by PNA staining (green). (B-C) Immunofluorescence analyses on retinal flat mounts of retinae 
infected with the AAV9-mCherry-GFP-LC3 vector at birth. (B) Representative images showing increased 
mCherry+/GFP– punctae (arrows) in cones of Cre+ mice indicating an increase in number of autolysosomes. 
Arrowheads indicate GFP+/mCherry+ autophagosomes. (C) Bar graphs representing average number 
GFP+/mCherry+ punctae (autophagosomes) and GFP-/mCherry+ punctae (autolysosomes) per cone cell. 
Data are representative of measurements in at least 60 cones over 3 different animals per genotype.  
****P < 0.0001 by Student’s t test. (D) Immunofluorescence analyses (red signal) on retinal flat mounts for 
phosphorylation sites on indicated proteins. Cones were detected by SW OPSIN (short wave length opsin: 
green signal) staining. In all panels blue is nuclear DAPI. Scale bars: 20μm 
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Therefore, while the data contradict the notion that activated mTORC1 inhibits 
autophagy, they are in agreement with a recent report which showed that unlike 
proliferating cells, post-mitotic neurons with TSC loss maintain autophagy through an 
AMP kinase dependent mechanism that activates ULK1 by phosphorylation at Ser555194. 
Consistent with that we observed increased phosphorylation in rd1-Tsc1cKO cones of both 
ULK1 sites, Ser757 and Ser555, as well as increased phosphorylation of AMPK (Figure 
3.2 D), suggesting that the mTORC1-dependent inhibition of ULK1 was overridden 
through activation of ULK1 by AMP-kinase. 
 
In agreement with an increased number of autolysosomes, proteins required for 
autophagosome formation such as ATG12 (Autophagy Gene 12), and ALFY (autophagy-
linked FYVE protein), a scaffold protein implicated in the selective degradation of 
ubiquitinated proteins were upregulated in cones (Figure 3.3 A)199,277. Moreover, 
quantification of lysosomes by counting the punctae positive for the lysosomal marker 
proteins LAMP1/2 (Lysosomal associated membrane protein 1 or 2) indicated an increase 
in the number of lysosomes in rd1-Tsc1cKO cones (Figure 3.3 B and C), corroborating the 
increase in number of autolysosomes. The increase in the number of lysosomes also 
coincided with increased nuclear translocation of the forkhead box protein O3 
(FOXO3A), a transcription factor that regulates the transcription of various autophagy-
related genes (Figure 3.3 D)212,213.  
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Figure 3.3:  Loss of Tsc1 in cones of rd1 mice leads to an upregulation of autophagy and lysosomal 
genes. Data shown are from rd1-mutant mice harboring the Tsc1c/c allele at 2 months of age. (A) 
Immunofluorescence analyses on retinal flat mounts for the indicated proteins (red signal). Cone layer was 
identified by PNA staining (green). (B) Bar graphs representing average number of LAMP1 and LAMP2 
punctae per cone. Values are representative of measurements performed in at least 60 cone cells across 2 
animals per genotype. ****P < 0.0001 by Student’s t test. (C) Representative immunofluorescence on retinal 
flat mounts for LAMP1 and LAMP2 (red signal). Cones were detected by cone ARRESTIN staining (green 
signal). (D) Immunofluorescence analysis of FOXO3A (red signal). Cones were detected by SW OPSIN 
staining (green signal). In all panels blue signal is nuclear DAPI. Scale bars: 20μm 
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Figure 3.4: Increase in expression of autophagy genes is dependent on mTORC1. Immunofluorescence 
analyses on retinal flat mounts for indicated proteins (red signal) in rd1 mice harboring the conditional 
alleles as indicated at 2 months of age. No difference is observed in the expression of autophagy genes (A) 
or FOXO3A (B) between Cre- and Cre+ littermates of Tsc1c/cRaptorc/c mice while nuclear FOXO3A is 
increased in rd1-Tsc1cKORictorcKO cones. Green is PNA in (A) and SW OPSIN in (B). Scale bars: 20μm 
 
The accumulation of p62 as well as the upregulation of ATG12 and ALFY were 
mTORC1 dependent, as they were unchanged in rd1-Tsc1cKO cones that lacked the 
mTORC1 accessory protein RAPTOR (Figure 3.4 A). The increased nuclear 
translocation of FOXO3A upon Tsc1 removal has been reported previously as well and 
could be a result of the inhibitory effect of activated mTORC1 on mTORC2158,160,278. 
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Reduced mTORC2 activity would then reduce AKT activity, which is a key kinase that 
regulates FOXO3A localization279. In this regard, nuclear FOXO3A staining was 
maintained in rd1-Tsc1cKO-RictorcKO cones which lack an active mTORC2 complex, 
absent in rd1-Tsc1cKO-RaptorcKO cones (Figure 3.4 B), and we demonstrated previously a 
reduction in AKT (Ser473) phosphorylation upon activation of mTORC1 (Figure 2.1 C). 
 
In summary, our data suggest that the defect in autophagy does not arise from autophagy 
initiation, autophagosome maturation or fusion with the lysosome. Since mTORC1 is a 
negative regulator of the transcription factor EB (Tfeb)258,259, a master transcription factor 
of lysosomal enzymes, the increased accumulation of autolysosomes could result from a 
deficiency of lysosomal enzymes due to increased mTORC1 activity. 
 
Tsc1 loss induces a shortage of free amino acids in cones. The autophagy defect in 
rd1-Tsc1cKO cones could cause an imbalance in cellular homeostasis if the increase in 
protein synthesis is not accompanied by a corresponding increase in protein turnover 
depleting the cell of free amino acids. To test this notion, we performed an experiment 
that exploits the mechanism of amino acid sensing by mTORC1. Under amino acid-
replete conditions, mTORC1 is recruited by the Rag GTPases to LAMP2 containing 
compartments where it encounters Rheb for activation280. Therefore, colocalization of 
mTORC1 with LAMP2 can be used to assess if the cell has a sufficiency of amino acids.  
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Figure 3.5:  mTOR and LAMP2 colocalization analysis reveals a shortage of amino acids upon Tsc1 
loss in cones.  Immunofluorescence analyses on retinal whole mounts of rd1 mutant mice harboring the 
conditional alleles indicated at 2 months of age. (A) Localization of mTOR to LAMP2-containing 
compartments in retinae of rd1-Tsc1c/c Cre- mice (arrowheads in higher magnification view). Localization 
is lost in Cre+ mice (lower row in A). Higher magnification view: the upper panel mTOR, lower panel 
mTOR and LAMP2. (B and C) Only Cre+ retinas of genotype indicated are shown with the upper row 
showing mTOR staining and lower row showing both mTOR and LAMP2. (B) mTOR:LAMP2 
colocalization is lost in rd1-RaptorcKOmice, but retained in rd1-RictorcKO mice. (C) mTOR:LAMP2 
colocalization in  rd1-Tsc1cKO mice can be restored by incubating retinas in DMEM media with or without 
glucose for 2 hours or by systemic administration of rapamycin (intraperitoneal), but not in retinae from 
rd1-Tsc1cKO mice upon concurrent removal of Raptor. Retinae were harvested two hours post-Rapamycin 
injection. In all panels red staining indicates mTOR, green LAMP2 and blue nuclear DAPI. Scale bars: 
20μm. Higher magnification images in (A): 1.5X original 
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We observed at 2 months of age in Cre- cones distinct focal mTOR staining that is 
strongly associated with LAMP2. However, in age-matched rd1-Tsc1cKO cones mTOR 
staining was diffuse and showing almost no colocalization with LAMP2 (Figure 3.5 A). 
To verify that the mTOR staining at the lysosome observed in Cre- cones was reflective 
of mTORC1, we repeated the experiment with rd1-RaptorcKO retinae, where 
colocalization was lost, and with rd1-RictorcKO retinae, where colocalization was 
maintained, indicating that the mTOR staining that colocalized with LAMP2 was in fact 
mTORC1 (Figure 3.5 B). 
 
To test if the absence of mTOR:LAMP2 colocalization in rd1-Tsc1cKO cones was caused 
by a shortage of amino acids, we explanted retinas from rd1-Tsc1cKO mice and incubated 
them in glucose-rich and glucose-free DMEM media (Figure 3.5 C). In both cases, short-
time exposure to regular media containing amino acids restored the mTOR:LAMP2 
colocalization. Similarly, a single injection of rapamycin, an allosteric mTORC1 
inhibitor, was also able to restore mTOR:LAMP2 colocalization in rd1-Tsc1cKO cones, but 
not in rd1-Tsc1cKO cones that also lacked Raptor (Figure 3.5 C).  
 
Together, the data suggest that loss of Tsc1 in cones of RP mice induces an imbalance in 
the supply and demand of amino acids, which could be responsible for the demise of 
cones seen between 2 and 4 months of age.  
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Rapamycin reverses the autophagy defect and improves cone survival upon Tsc1 
loss.  
          
Figure 3.6: Rapamycin reverses the autophagy defect and improves cone survival upon Tsc1 loss in 
wild type mice. (A) Immunofluorescence analysis on retinal flat mounts from Tsc1cKO mice showing 
clearance of p62 aggregates in cones (upper panel, red signal; green: PNA) and recovery of cone arrestin 
(lower panel, red signal) expression upon delivery of rapamycin between P28 to 4 months of age. Images 
were acquired at 1mm radius from the optic nerve (Sector 1) Scale bars: 20μm. (B) Quantification in Sector 
1 (1mm radius, as in Figure 3.1) of cone-arrestin positive cones in wild type mice at 4 months of age. Data 
are representative of at least 3 mice in each case. **P < 0.01 by Student’s t test. 
 
The restoration of colocalization between mTOR and LAMP2 in rd1-Tsc1cKO cones upon 
rapamycin administration (Figure 3.5 C) indicates that autophagy was restored resulting 
in the release of free amino acids. To test whether the p62 and ubiquitin aggregates or the 
lack of free amino acids cause cones to die in rd1-Tsc1cKO mice, we performed a long-
term rapamycin treatment. In Chapter II, we showed that rd1-Tsc1cKO mice display a 
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decline in cone survival between 2 and 4 months of age. Similarly, removal of Tsc1 in 
cones of wild type mice (Tsc1cKO) causes loss of cone arrestin expression by 4 months of 
age (Figure 3.6 B). Because loss of mTORC1 activity did not affect cones in a wild type 
background but accelerated cone death during disease, we first administered rapamycin to 
Tsc1cKO mice, where repeated injections between 1-4 months of age (18 in total) did clear 
p62 and ubiquitin aggregates and also restored cone arrestin expression in Tsc1cKO mice 
(Figure 3.6 A and B). 
 
In rd1-Tsc1cKO mice where mTORC1 activity is critical to promote cone survival, we first 
tested the effect of rapamycin between 1-2 moths of age, a time window in which cone 
survival remains stable at around 78% (Figure 2.11). While one injection of rapamycin at 
2 months of age was not able to clear p62 and ubiquitin aggregates, repeated injections at 
an interval of 5 days were sufficient to clear p62 and ubiquitin aggregates without 
affecting cone survival (Figure 3.7 A and B). The 5 days interval period was based on the 
time window it took for pS6 levels to recover in cones of rd1-Tsc1cKO mice after one 
rapamycin injection (Figure 3.7 C and D).  
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Figure 3.7: Effect of rapamycin administration in rd1-Tsc1c/c mice. (A) Immunofluorescence analyses 
on retinal flat mounts for p62 and UBIQUITIN (red signal, as indicated) in rd1-Tsc1cKO mice at 2 months of 
age upon vehicle or rapamycin administration. (B) Quantification of cone survival in rd1-Tsc1cKO mice at 2 
months of age when administered with vehicle or rapamycin once every five days from P28 to 2 months. 
(C-D) Kinetics of recovery of phosphorylation of S6 on retinal flat mounts of rd1-Tsc1cKO mice when 
administered with vehicle or rapamycin. (C) Immunofluorescence for phospho-S6 (red signal) on retinal 
flat mounts harvested 2 or 5 days after injection with vehicle or rapamycin. Green is PNA. Scale bar: 20μm 
(D) Western blot for phospho-S6 on mice harvested 1, 3 or 5 days after injection with rapamycin. The data 
show that S6 phosphorylation is almost fully recovered by day 5 after injection. Green signal in (A) and (C) 
is PNA. Scale bar: 20μm 
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Extended injections of rapamycin (18 in total) up to 4 months of age, however, led to a 
drop in cone survival when compared to vehicle-injected mice (Figure 3.8 A), suggesting 
that mTORC1 was inhibited too often over the 3 months time period. We therefore 
performed two additional treatment regimens reducing the frequency of administration by 
three-fold each time. This led to a dose dependent increase in cone survival with 6 
injections being at par with vehicle treated mice and 2 injections showing a significant 
improvement in cone survival by 4 months of age (Figure 3.8 A and B). Post-injection 
analysis of p62 aggregates at 4 months showed that neither 6 nor 2 injections of 
rapamycin were sufficient to clear p62. (Figure 3.8 C, only data from 6 injections is 
shown) The data therefore suggests that clearance of p62 is not required to improve cone 
survival, since 2 or 6 single injections of rapamycin was not sufficient to clear p62 
(Figure 3.7 A and 3.8 C), however one injection was sufficient to facilitate autophagy 
releasing free amino acids that directed mTOR to the lysosome for at least 14 days 
(Figure 3.8 D).  
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Figure 3.8: Dose-dependent effect of rapamycin administration on cone survival of rd1-Tsc1c/c mice. 
(A) Quantification of cone survival in rd1-Tsc1cKO mice at 4 months of age upon injection with vehicle or 
rapamycin starting at P28. Number of rapamycin injections is indicated in bar. Data are representative of at 
least 6 mice in each group. *P < 0.05, **P < 0.01 by Student’s t test. (Scale bars: Upper panel: 1mm and 
lower panel: 50um) (B) Representative retinal flat mounts of rd1-Tsc1cKO mice at 4 months of age showing 
more central cones when two injections of Rapamycin were administered (red signal: cone arrestin; Scale 
bars: 1mm). (C) Immunofluorescence analyses for p62 (red signal) at 4 months of age in rd1-Tsc1cKO mice 
treated with vehicle or 6-injections of rapamycin. (D) Dynamics of mTOR (red signal) localization with 
LAMP2 (green signal) post rapamycin injection in rd1-Tsc1cKO mice with upper row showing mTOR 
staining and lower row showing both mTOR and LAMP2. 
87
Increased mTORC1 activity by loss of Pten maintains autophagy and is more 
beneficial for long-term cone survival. Since intermittent inhibition of constitutively 
activated mTORC1 improved cone survival at 4 months of age when compared to 
constitutively activated mTORC1 alone we investigated the effect of lower levels of 
mTORC1 activation on autophagy, mTORC1 localization and long-term cone survival. 
We showed in Chapter II that loss of Pten in cones activates mTORC1 to a lesser extent 
than Tsc1 loss. Consequently, Pten loss in cones of RP mice (rd1-PtencKO mice) results in 
a smaller cone survival effect at 2 months of age than seen with Tsc1 loss. Interestingly, 
in rd1-PtencKO retinae we found no accumulation of p62 or ubiquitin in cones at 2 months 
of age, suggesting that autophagy is not impaired with lower mTORC1 activation (Figure 
3.9 A). Concordantly, mTOR:LAMP2 colocalization in cones was similar between Cre- 
and Cre+ littermates (Figure 3.9 B), with only a moderate increase in lysosomes per cone 
as assessed by LAMP1 positive punctae (Figure 3.9 C). The data suggest that while 
autophagy is increased, it is not impaired maintaining a free amino acid pool despite the 
increase in protein translation predicted to occur upon loss of Pten. In agreement with 
these findings, we did not observe any increase in ULK1 phosphorylation at both sites 
nor in AMP kinase phosphorylation (Figure 3.9 D), suggesting that autophagy is 
maintained at a steady state.  
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Figure 3.9: Moderate increase in mTORC1 activity by loss of Pten does not cause a defect in 
autophagy. Data shown are from rd1-Ptenc/c mice, unless indicated otherwise. (A) Immunofluorescence 
analysis on retinal flat mounts for indicated proteins (red signal) at 2 months of age (green: PNA). (B) 
Immunofluorescence analysis on retinal flat mounts for mTOR (red signal) and LAMP2 (green signal) in 
Cre+ mice at 2 months of age.  Upper panel shows only mTOR, lower panel shows colocalization with 
LAMP2 (Scale bar: 20μm). Bar graphs represent percentage of mTOR punctae that colocalize with LAMP2 
per cone. Data from rd1-Tsc1cKO mice (representative images in Figure 3.5 A) is provided for comparison. 
The data represent values obtained from at least 60 cones across 2 animals per genotype (****P < 0.0001 by 
Student’s t test). (C) Immunofluorescence analysis on retinal flat mounts for LAMP1 (red signal) in Cre- 
and Cre+ mice at 2 months of age. Cones were identified by cone arrestin antibody (green signal; Scale bar: 
20μm). Bar graphs showing number of LAMP1 punctae per cone. Data represent values obtained from at 
least 60 cones across 2 animals per genotype (****P < 0.0001 by Student’s t test). (D) Immunofluorescence 
analysis on retinal flat mounts for indicated proteins (red signal) at 2 months of age (green: SW OPSIN) 
Scale bars: 20μm 
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In wild type mice, we observed only occasional accumulation of p62 in cones of PtencKO 
mice when compared to mice where Tsc1 was removed in cones (Figure 3.10 A). This 
accumulation was not detrimental to cone function and survival up to 1 year of age  
(Figure 3.10 B and C).  
     
Figure 3.10: Loss of Pten does not affect cone survival or function in a wild type background. Data 
presented are from Ptenc/c mice, unless indicated. (A) Immunofluorescence analysis (red signal) on retinal 
flat mounts for p62 in cones of Ptenc/c mice at 2 months of age. Arrow indicates p62 aggregate in cone 
segment of Cre+ mice. Green is PNA. Scale bar: 20μm. The bar graph represents quantification of 
percentage of cones with p62 aggregates in retinae from PtencKO and Tsc1cKO (representative image in 
Figure 3.6A) mice at 2 months of age. p62 aggregation was not detected in  Cre- mice in either genotype 
and hence was not included in the graph. Data are representative of measurements in at least 100 cone 
segments across 2 animals per genotype. **P < 0.01 by Student’s t test. (B) Evaluation of cone function by 
photopic ERG recordings showing average b-wave amplitudes. We did not measure a significant difference 
between Cre- and Cre+ littermates at any time point. Data are representative of at least 6 mice in each 
group. (C) Quantification of cone number based on cone arrestin staining in two retinal sectors as described 
in Figure 3.1. No difference was observed up to 1 year of age between Cre- and Cre+ littermates. Data are 
representative of at least 2 mice in each group. 
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Together these findings led us to test if long-term protection of cones is improved upon 
loss of Pten when compared to loss of Tsc1. In Chapter II, we evaluated the protective 
effect of Pten and Tsc1 loss in cones of RP mice up to 8 and 12 months of age, 
respectively. At one year of age there was no cone protection upon loss of Tsc1, however; 
there was more than a 2-fold increase in cone survival in rd1-PtencKO mice when 
compared to Cre– littermates and cone survival was also significantly higher when 
compared to loss of Tsc1 (Figure 3.11 A and B). A linear regression analysis shows that 
while the initial effect upon loss of Pten is less robust, the decline over time is not as 
steep when compared to loss of Tsc1 (Figure 3.11 C).  
 
 
Figure 3.11: Moderate increase in mTORC1 activity by loss of Pten is more benefical for long-term 
cone survival. (A) Representative retinal flat mounts of rd1-Ptenc/c mice at 12 months of age showing 
improved cone survival in Cre+ mice (red: cone arrestin; Scale bar: 1mm). (B) Quantification of cone 
survival at 12 months of age comparing data obtained from rd1-PtencKO mice with rd1-Tsc1cKO. *P < 0.05 by 
Student’s t test. (C) Linear regression of cone survival over time in rd1-Tsc1cKO and rd1-PtencKO mice. Loss 
of Pten results in a more gradual decline in cone survival, as seen by the smaller slope.  
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In summary the data indicate that moderate mTORC1 activation that does not impair 
autophagy is more beneficial for long-term cone survival as both, glucose and amino acid 
metabolism are balanced, suggesting that therapeutic intervention with few mTORC1 
target genes or mild mTORC1 activators is an obtainable goal for long-term vision 
stabilization in individuals with RP. 
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CHAPTER IV 
 
Discussion 
 
Loss of vision can drastically impact the quality of life. While RP has been studied for 
several decades, and many of the genes that cause the disease are known, there is still no 
treatment available for patients affected by the disease. This may partly arise from the 
fact that not many research efforts have focused on understanding how cones, which have 
highly specialized structural and functional requirements, regulate their metabolic 
demands. In this study, we show that cell autonomous activation of mTORC1 mediated 
by loss of either Tsc1 or Pten is sufficient to promote long-term survival of cones in RP. 
Our data showing almost a wild type distribution of cones at 2 months of age upon loss of 
Tsc1 in the rd1 mouse model (Figure 2.6 A and B) holds great promise, since this model 
is one of the fastest progressing models of RP. Because cone death is also significantly 
delayed in the Rho-/- model (Figure 2.14), our approach is mutation-independent and can 
be applied to a broad spectrum of rod-specific mutations in RP. Our research also 
addresses a longstanding question of non-autonomous cone death and suggests that the 
secondary loss of cones in RP is principally caused due to a shortage of nutrients, 
particularly of glucose in cones. While unwarranted secondary effects such as the 
inhibition of autophagy accompany constitutive mTORC1 activation, our data suggest 
that it is possible to overcome this drawback by regulating the extent of mTORC1 
activation (Figure 3.8). In this regard, activation of mTORC1 by loss of Pten, promotes 
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cone survival for up to 1 year of age without hampering autophagy (Figures 3.9 and 
3.11). Thus far, no other study has reported significant protection of cones in the rd1 
mouse model at this late time point. Our comprehensive characterization of the role of the 
insulin/mTOR pathway members in cone PRs also highlights how neurons may 
differentially utilize this pathway under normal and nutrient stress conditions encountered 
during disease, which may have implications in other neurodegenerative diseases as well. 
We will now elaborate on the significance of our findings.  
 
Role of mTOR in cone homeostasis and disease: Various growth factors that promoted 
cone survival in RP models13,88,89,93 may act through increasing PI3K activity, since the 
kinase functions as a common upstream component of various signaling pathways281. 
PI3K activity is critical for cones as its loss leads to progressive decline of cone survival 
and function218,219. In this study we show that removal of mTORC1, which is downstream 
of PI3K, causes approximately a 50% decline in cone survival during disease (Figure 2.4 
A and B), suggesting that mTORC1 is critical to allow cones to adapt to conditions of 
nutrient stress. However, loss of mTORC1 did not have any effect in wild type mice 
where cones do not encounter nutrient stress (Figure 2.5). While we presented data up to 
2 months of age, a parallel study characterizing the long-term effect of mTORC1 ablation 
in wild type cones performed in our laboratory found that neither cone survival nor 
function is affected upon loss of mTORC1 for up to 1 year of age282. Most tissues are 
severely affected upon removal of Raptor, given the central role for mTORC1 in 
regulating the metabolic transcriptome, especially in cells with high metabolic 
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demands283-285. It is therefore surprising that this kinase was not required for survival of 
cones under normal conditions, suggesting that PI3K-dependent pro-survival signals are 
independent of mTORC1 in wild type cones. Consistent with these data, we do not 
observe an increase in the expression of mTORC1-target genes involved in cell 
metabolism in wild type cones upon constitutive activation of mTORC1 (Figure 2.12). 
Therefore, our data suggests that mTORC1 functions only under conditions of stress to 
increase expression of critical glycolytic genes. This is further supported by the finding 
that the expression of these genes increases gradually over time from P21 to 2 months of 
age, suggesting that the increase was in response to the progression of the disease (Figure 
2.10).  
 
Cones have considerably shorter outer segments (OS) when compared to rods and 
therefore, the requirement to synthesize membrane is lesser. Cones may therefore utilize 
less NADPH and consequently consume less glucose than rods. It however, remains to be 
determined if rods utilize mTORC1 to fulfill their metabolic requirements. On the 
contrary, the requirement for ATP may be higher in cones, since they function throughout 
the day and hence need ATP to constantly re-equilibrate membrane potential. However, 
under disease conditions, there is a shortening of cone OSs, which necessitates cones to 
diverge more glucose into biosynthetic pathways to maintain their OS, since PR function 
is tightly linked to OS integrity. The fact that cones may depend more on glucose during 
disease is demonstrated by the finding that mTORC1 activity, as evaluated by 
phosphorylation of S6, is barely detectable in cones under normal conditions, while it is 
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increased in cones of rd1 mice (Compare Figure 2.3B with Cre- images from Figure 2.2C 
or 2.6D). Similarly, the expression of mTORC1 target genes like GLUT1 and HIF-1α is 
increased during disease in cones when compared to wild type cones (Compare Cre- in 
Figure 2.9 with Figure 2.12). Concordantly, removal of mTORC1 severely affects cones 
in RP since they are not able to synthesize NADPH to maintain their OSs. Cones can still 
generate ATP from lactate derived from Müller glia cells, since cone-glial interactions 
are not predicted to be affected in RP, unlike cone:RPE interactions129. In fact, neurons 
have been reported to use lactate to fuel oxidative metabolism286,287. Cones are known to 
remain dormant or non-functional in RP for extended periods of time following the loss 
of their OS288. This may be due to the fact that they still have sufficient ATP that affords 
survival in the absence of an OS. Together, the data suggest that the energy requirements 
for cones vary under nutrient replete and nutrient stressed conditions, which results in the 
differential utilization of mTORC1 under the two scenarios.  
 
Loss of mTORC2 generally has a milder phenotype than loss of mTORC1 and this was 
also mirrored in our study, where its loss did not affect cone survival in either wild type 
or RP mice267,289.  
 
Constitutive activation of mTORC1 upon loss of the TSC in cell culture systems has been 
shown to render cells sensitive to complete withdrawal of glucose290. Loss of TSC 
increases the rate of glycolysis, which causes cells to become addicted to glucose. Under 
conditions of glucose withdrawal, the increased demand of TSC-null cells is not balanced 
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by a corresponding increase in supply, which decreases the ATP:ADP ratio, leading to 
the activation of an energetic stress response mediated by AMPK and subsequent 
induction of apoptosis. Under these conditions, inhibition of mTORC1 by rapamycin 
confers a survival advantage to cells with loss of TSC. Interestingly, low glucose 
conditions (as opposed to complete withdrawal) confer a survival advantage to TSC null 
cells291. This is because increased mTORC1 activity allows for the expression of 
transporters and other metabolic genes that allow cells to counterbalance the shortage of 
glucose. Similar to findings in cell culture, we find that loss of TSC confers a survival 
advantage to cones in RP mice (Figure 2.6 A and B). Retinae from rd-Tsc1cKO mice have 
increased NADPH levels (Figure 2.8 B) suggesting that glucose uptake and divergence 
into the PPP was increased. Since NADPH is required for lipid and membrane synthesis, 
the increase in NADPH may have facilitated the synthesis of OSs thereby preventing the 
shortening of cone OSs normally seen during disease. Consequently, OS length and width 
are maintained between P21 and 2 months of age in rd1-Tsc1cKO cones (Figure 2.8 D), 
which also improves cone function (Figure 2.6 C). NADPH is also required to recycle the 
visual chromophore that is required for PR function. Therefore, an overall healthier and 
better functioning cone PR is also likely to survive longer. Our data however, does not 
establish that the increase in NADPH and thus, improved cone survival was due to 
elevated expression of metabolic genes like HKII or G6PD. Further, we also do not show 
that glucose uptake was indeed increased in cones upon loss of Tsc1. Loss of the 
protective effect upon concurrent loss of Tsc1 and HkII or any other metabolic gene, or 
measuring uptake of fluorescent or radiolabelled glucose analogs would unequivocally 
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address if improved cone survival was mediated by improving glycolytic metabolism of 
cones. 
 
Besides glucose, amino acids and growth factors are also critical to maintain mTORC1 
activity, and the lysosome is the site where these inputs converge to regulate mTORC1. 
Amino acids mediate the recruitment of mTORC1 to the lysosome, where GTP-bound 
Rheb, which in turn is regulated by growth factors, activates it196. Recent studies in cell 
culture have shown that TSC2 localization is also sensitive to amino acids173. A 
deficiency in amino acids promotes TSC2 localization to the lysosome, where it inhibits 
Rheb, subsequently inhibiting mTORC1 activity. Amino acids therefore exert a dual 
regulation of mTORC1 activity through mTORC1 and TSC2 localization. Consequently 
upon loss of TSC, cells are sensitive to amino acid withdrawal since they are unable to 
completely turn off mTORC1 activity. Under these conditions, mTORC1 is not 
completely withdrawn from the lysosome, thereby being still active despite the shortage 
of amino acids. Therefore, loss of TSC results in an inhibition of autophagy even under 
amino acid starvation conditions. What do these studies tell us about the situation in 
cones? We reported that upon loss of Tsc1, the mTOR staining is diffuse and 
predominantly not colocalized with the lysosome. However, our quantification revealed 
that about 20% of LAMP-2 puncate are still positive for mTOR upon loss of Tsc1 (Figure 
3.9 B). This residual mTORC1 at the lysosome may be sufficient to mediate an inhibition 
of autophagy. Therefore, while loss of Tsc1 confers an initial survival advantage to cones, 
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the efficiency of cone survival eventually declines over time, since they are not able to 
regulate mTORC1 activity in order to promote autophagy.  
The reduced localization of mTORC1 at the lysosome upon loss of Tsc1 is also indicative 
of a shortage of amino acids because short-term incubation of retinae in glucose-free 
media is sufficient to restore mTOR:LAMP2 colocalization (Figure 3.5). Does the lack of 
amino acids arise because of reduced flow from the RPE, similar to glucose or is it the 
inhibition of autophagy that in turn, causes a shortage of amino acids or a combination of 
both? To address this question, we evaluated mTOR localization from P21, when cone 
death just initiates.  
 
Figure 4.1: Dynamics of mTOR localization during disease. Immunofluorescence analyses on retinal 
whole mounts from rd1-Tsc1c/c (A) or Tsc1c/c (B) mice. Arrowheads in (A) indicate absence of mTOR (red 
signal) and LAMP2 (green signal) colocaliation, while arrows are used to depict colocalization. Green 
signal in (B) represents either the cone marker PNA or LAMP2, as indicated 
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Interestingly, we found that mTOR was not localized to the lysosome in either Cre- or 
Cre+ cones at P21, by P42 however; mTOR localization is restored to the lysosome in 
Cre- cones, while it continued to remain diffuse in Cre+ cones (Figure 4.1 A). In cones of 
wild type mice, mTOR was found at the lysosome, suggesting that its primary 
localization in the absence of nutrient stress in cones is at the lysosome (Figure 4.1 B). 
The data therefore suggest that cones also experience a shortage of amino acids at the 
onset of cone death. Cones of Cre- mice are able to initiate and maintain autophagy, 
which releases amino acids resulting in relocalization of mTOR to the lysosome, unlike 
Cre+ cones, which furthers adds to the shortage of amino acids upon loss of Tsc1. 
Therefore, while glucose metabolism is improved on one hand, there is an amino acid 
crisis on the other hand. The reduction is ERG responses as well as progressive loss of 
cone-arrestin expression in wild type mice (Figure 3.1 A-C) further suggest that chronic 
activation of mTORC1 is not beneficial to cone PRs.  
 
In contrast to Tsc1 null cells, Pten null cells are able to turn off mTORC1 activity173, 
which allows for the induction of autophagy in response to amino acid withdrawal. This 
is because upon loss of Pten, TSC2 is able to localize to the lysosome and inhibit 
mTORC1 under conditions of amino acid starvation. This may explain why loss of Pten 
results in a more sustained survival effect in rd1 cones (Figure 3.11). While loss of Pten 
increased the number of cones positive for phospho-S6 in rd1 mice at the onset of cone 
death (Figure 2.2), it would be interesting to determine if there is eventually a reduction 
in mTORC1 activity to adapt to the nutrient shortage, which allows for the maintenance 
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of autophagy, as reported in cell culture studies173. The challenge in evaluating the 
kinetics of S6 phosphorylation over time is that cell death is constantly ongoing in rd1 
mice and hence, a reduction in S6 phosphorylation may not necessarily indicate a 
reduction in mTORC1 activity over time. However, while Pten or Tsc1 are principally 
deleted in every cone cell in their respective cases, loss of Pten still induces S6 
phosphorylation in fewer cones when compared to loss of Tsc1 (Compare Figure 2.2C 
with Figure 2.6D), which suggests that cones with loss of Pten are more proficient at 
regulating mTORC1 activity. Moreover, since we barely observe an accumulation of p62 
or ubiquitin upon loss of Pten (Figure 3.9), the data suggest that mTORC1 activity is 
regulated in a manner that affords cone survival as well as maintains autophagy. 
Consequently, mTOR is retained at the lysosome, indicating a sufficiency of amino acids.  
 
In summary, while of our findings parallel observations made in cell culture systems, 
they also provide new insights into how neurons may regulate mTOR activity in response 
to stress conditions. It is important to appreciate that cells in vivo may never experience 
conditions that are used in cell culture studies. Signaling events may be more dynamic 
(such as change in mTOR localization in Cre- mice) and hence, need to be examined over 
the course of the disease progression. Our studies also report other cell-type specific 
differences in the regulation of insulin/mTOR signaling. For example, loss of Pten 
usually activates both mTOR complexes and AKT, and Pten-null tumors are often 
dependent on mTORC2 activity137,292. We report that loss of Pten leads to a reduction of 
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mTORC2 activity (Figure 2.2 C) and also that mTORC2 was dispensable for cones 
(Figure 2.4).  
 
Metabolic model of cone death and its relation to oxidative stress and rod-derived 
cone-viability (RdCVF) factor models: Cellular redox potential is tightly linked to 
nutrient availability. For example, NADPH is used to reduce oxidized glutathione, which 
serves to scavenge many free radicals135. Therefore, in addition to maintaining cone OS 
length and function, the increase in NADPH may also be used to reduce glutathione to 
counteract oxidative stress. The metabolic model of cone death is thus also consistent 
with oxidative stress as being causative for cone death in RP. However, oxidative stress 
alone is unlikely to be the main factor for cone death since antioxidants or over-
expression of genes that counteract oxidative stress have not achieved the same protective 
effect as seen by loss of Tsc1 in the rd1 mouse model at 2 months of age104,118,119.  
 
RdCVF is a trophic factor that is secreted by rods and shown to have protective effects on 
secondary cone death in RP. Recently, a study found that RdCVF binds to basigin-1, a 
receptor that is present in PRs, which in turn stimulates GLUT1 activity125. The authors 
showed that RdCVF treatment improved glucose uptake and aerobic glycolysis in cone-
enriched cultures and a mutant version of RdCVF that is unable to bind basigin-1 does 
not mediate cone survival in rd1 mice. Therefore, RdCVF and mTORC1 seem to 
promote cone survival through the same mechanism of improving glucose levels in 
cones. However, we argue that the kinetics of rod and cone death in various models of 
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RP13 exclude the possibility that a tropic factor secreted by rods plays a major role in 
cone survival. This is because cone survival continues for extended periods of time even 
in the absence of rods, which questions the extent to which the factor is important for 
cone survival. Nonetheless, these new findings on the mechanism of RdCVF action 
suggest that improving cone metabolism is ultimately the key factor to extend their 
survival, which suggests that the overall cause of cone death is a shortage of metabolites, 
particularly of glucose.  
 
Apoptosis linked to low NADPH levels in cones: An understanding of the cell death 
mechanisms for cone death in RP remains largely elusive. Identifying a cell death 
mechanism may shed light on the overall cause of cell death, as some mechanisms 
require specific stress conditions or triggers. In this regard, the identification of Casp2 as 
the first apoptotic mechanism for cone death in RP further corroborates the notion that 
low NADPH levels are a contributing factor to cone death and supports the overall idea 
of a nutrient shortage in cones. However, a delay in cone death in only seen at late stages, 
by 20 weeks of age (Figure 2.13 C and D). This could be due in part to the involvement 
of necrosis during the initial phase of cone death. A recent report showed that early cone 
death in the rd10 mouse model of RP includes necrotic cell death242. Rod death 
progresses slightly slower in the rd10 model than in the rd1 model, yet it is still faster 
than in the Rho–/– model. The electron microscopic analyses performed in that study 
revealed several cone nuclei with necrotic features at early stages of cone death. 
Additionally, the study showed that inhibition of necrosis reduces the number of necrotic 
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nuclei and delays early cone death. Nonetheless, a greater number of cone nuclei showed 
signs of apoptotic cell death, even at early stages. Early necrotic cone death could be due 
to the rapidly occurring structural insult on the retina because of the rather rapid loss of 
rods. Once the necrotic phase ceases, the remaining cones may die by apoptotic 
mechanisms, including the activation of CASP2 induced by low NADPH levels. 
Interestingly, preliminary data from our laboratory shows that loss of Rip3 in the rd1 
model shows no protective effect on cones by 6 weeks of age, when it conferred 
protection in the rd10 model. The lack of protection in the rd1 model may be attributed to 
the fact that the necrotic phase is rather short lived and cone death progresses very 
rapidly during this period (94% cones at P21 to 65% by P24 in Cre- mice, Figure 2.11). 
Therefore, any approach including loss of Tsc1 is unable to prevent this initial rapid 
decline (97% cones at P21 to 74% by P24 in Cre+ mice, Figure 2.11). However, once the 
necrotic phase ceases, the metabolic gene regulatory network that is progressively 
activated by mTORC1 effectively prolongs cone survival.  
 
In combination with early necrosis and Casp2 mediated apoptosis, there are likely 
additional, as yet unidentified cell death mechanisms that contribute to cone death. These 
could explain why loss of CASP2 does not result in a more profound effect. One would 
expect these mechanisms to be linked either directly or indirectly to low intracellular 
energy levels, as improving cell metabolism through activation of mTORC1 effectively 
delays cone death. For example, reduced NADPH levels could induce cell death through 
oxidative stress before CASP2 is activated. Thus, removal of one of the cell death 
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mechanisms such as loss of CASP2, or treatments with antioxidants, is not sufficient to 
achieve the same effect that is seen with treating the overarching problem of starvation 
through loss of Tsc1.  
 
Autophagy upon loss of Tsc1 in cone PRs and implications in Tuberous Sclerosis: 
Loss of function mutations in TSC1/TSC2 genes lead to tuberous sclerosis complex 
(TSC), a multi-system disorder characterized by benign tumors and dysfunction of the 
central nervous system causing various developmental and behavioral problems271. Since 
mTORC1 is a positive regulator of growth, giant cells with increased mitochondria and 
abnormal lysosomes are a hallmark of TSC293. Previous studies have shown that loss of 
Tsc1/2 in neurons and other cell types increases endoplasmic reticulum and oxidative 
stress and induces autistic-like behavior in mice195,294. While the increase in mitochondria 
may result in oxidative stress, the aberrant lysosomes may be attributed to the inhibition 
of autophagy. Loss of Tsc1 in cones results in phosphorylation of ULK1 at Ser757, which 
inhibits autophagy initiation, however, autophagy is promoted in neurons due to 
phosphorylation of ULK1 at Ser555 by AMPK (Figure 3.2 D). Unlike proliferating cells, 
neurons cannot divide to dilute undigested cellular contents and hence, they continue to 
accumulate it resulting in the gradual buildup of lysosomal stress. How AMPK gains 
access to ULK1 in the presence of mTORC1 is not known, nonetheless phosphorylation 
of ULK1 by AMPK appears to be a quality control feedback mechanism to promote 
autophagy in order to counteract stress in neurons. Brain tumors (cortical tubers) of 
patients with TSC also display an increase in LC3-II, the lipidated form of LC3, which 
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forms part of the autophagosome, suggesting an accumulation of autophagic cargo194. 
While the small percentage of cones cells in the retina may complicate the assessment of 
the ratio of LC3-I to LC-II by western blot, our LC3 reporter assay convincingly 
demonstrates an active autophagy flux (Figure 3.2 B and C). It is interesting to note that 
the total number of yellow and red punctae (autophagosomes and autolysosomes, 
respectively) is higher in rd1-Tsc1cKO cones, indicating an overall increase in the total 
number of autophagy vesicles. On one hand, this could be due to an increase in 
autophagy initiation, since we also observe an increase in expression of autophagy and 
lysosomal genes (Figure 3.3 A-C). However on the other hand, the number of 
autophagosomes remains the same between Cre- and Cre+ retinae, suggesting that there is 
only a shift towards more number of autolysosomes and that autophagy initiation is not 
increased per se (Figure 3.2 C). Nonetheless, the accumulation of autolysosomes suggests 
that rd1-Tsc1cKO cones are unable to properly digest the autolysosomal contents, resulting 
in their accumulation over time. This could result from either a defect in lysosomal pH 
and/or a shortage of lysosomal enzymes. The first scenario is unlikely because if 
lysosomal pH were altered, we would not observe quenching of the GFP signal in our 
LC3 reporter assay. In order to test if the accumulation of autolysosomes resulted from a 
deficiency of lysosomal enzymes, we examined the expression of Tfeb, a master 
transcription factor of lysosomal genes and enzymes, since activation of mTORC1 
excludes Tfeb from the nucleus, thereby preventing its transcriptional activity258,259. Use 
of two commercial antibodies against TFEB did not show any expression changes 
between Cre- and Cre+ retinae. As a control, we performed the staining on cones lacking 
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Raptor, where Tfeb should constitutively localize to the nucleus. However, we did not 
detect any change with either antibody (data not shown). Therefore, we can only 
speculate that a lack of TFEB activity may be responsible for the autophagy defect. In the 
event that our hypothesis is right, over-expression of Tfeb using rAAV vectors may be 
the most straightforward approach to correct this defect. In addition to examining TFEB 
expression, lysosomal activity can be evaluated in colorimetric or fluorometric lysosomal 
activity assays, which assess the activity of lysosomal enzymes such as Cathepsin B/D, in 
retinal tissue extracts or following isolation of retinal lysosomes. The small percentage of 
cones in the retina would however, make it more complicated to perform and interpret 
these assays. Therefore, fluorescent activity assays that assess real-time lysosomal 
activity in vivo, similar to the fluorescent caspase activity assay that we have used, may 
be a feasible approach.  
 
On the contrary, cones in Cre- mice may suffer from a shortage of lysosomal genes 
because they have very low number of autolysosomes when compared to the number of 
autophagosomes (less than 1:3, Figure 3.2 C). In neurons that maintain a normal 
autophagy flux, the ratio between autophagosomes and autolysosomes should ideally be 
1:1194. Therefore, while the requirement for lysosomal genes is fulfilled by activation of 
mTORC1, it introduces a defect in the termination stages of the process. In contrast, loss 
of Pten mediates a small increase in lysosomal genes (Figure 3.9 C), which may be 
sufficient to promote autophagy without affecting the termination stages.   
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Are there other mechanisms one could harness to sustain the survival effect obtained 
upon loss of Tsc1 beyond 2 months of age? Elimination of autophagy genes or p62 may 
not be the right approach because while this may prevent the formation of protein 
aggregates, removal of autophagy altogether may have detrimental consequences on the 
cell198. In line with this, tumorigenesis of TSC tumors was lost upon removal of Atg5 or 
p62193. Further, the detection of selective autophagy adaptor proteins like ALFY in cones 
suggests that the process is highly specific for degradation of ubiquitinated 
proteins/organelles. Therefore, facilitating another degradation mechanism such as the 
ubiquitin proteasome system cannot compensate for a defect in autophagy. Based on a 
recent report on the regulation of the proteasome by mTORC1, proteosomal activity may 
in fact be elevated in cones upon loss of Tsc1202. Therefore, while both mechanisms are 
involved in the degradation of ubiquitinated proteins, each may have exclusive targets 
that accumulate upon impairment of the corresponding degradation mechanism.  
 
Disaccharides like trehalose have been shown to enhance autophagy and improve 
neuronal survival in mouse models of diseases like amyotrophic lateral sclerosis, which 
are caused due to abnormal aggregation of proteins295,296. This sugar is interesting because 
unlike rapamycin, it induces autophagy without affecting mTORC1 activity. We 
therefore administered trehalose to rd1-Tsc1cKO over a 4-month period. However, it did 
not result in any significant improvement in cone survival (53.2±3.3%), compared to 
control animals (51.1±4.5%). The reason why trehalose may not be effective in our case 
is that it is believed to promote autophagy by increasing expression of FOXO1 and other 
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autophagy genes295. Therefore, while its administration may promote autophagy in 
neurons with a functional TSC complex, cones that lack TSC already have an elevated 
expression of FOXO and autophagy genes. Therefore, trehalose and other agents that 
increase the basal level of autophagy may not be an effective strategy to correct the 
problem of autolysosome accumulation. While on one hand, the increased nuclear 
translocation of FOXO3A provides an explanation for the increase in autophagy and 
lysosomal genes in rd1-Tsc1cKO cones; on the other hand, FOXO activation is also known 
to promote expression of various pro-apoptotic proteins of the Bcl-2 family209. One study 
performed in Drosophila melanogaster eye-antennal disc tissue showed that concurrent 
loss of Tsc1 and Foxo resulted in an increase in organ size when compared to loss of Tsc1 
alone, suggesting that increased Foxo activation restricts pro-growth functions of 
mTORC1278. Therefore, the role of increased FOXO activation in rd1-Tsc1cKO cones 
needs to be further investigated in order to determine whether it is beneficial or 
detrimental to cones.  
 
Another potential strategy to extend survival of rd1-Tsc1cKO cones would be to 
investigate the cell death mechanism that leads to the eventual loss of rd1-Tsc1cKO cones. 
While Caspase-2 is activated in cones of rd1 mice in response to low NADPH levels, 
loss of Tsc1 may induce activation of caspases such as caspase-3, -9 and -12, as 
previously reported due to activation of endoplasmic reticulum (ER) and other stress 
responses297. Therefore, gene therapy to silence caspases or over-expression of XIAP 
may be a potential strategy to extend survival of rd1-Tsc1cKO cones. Since caspase 
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inhibitors are not efficient at crossing the blood-retinal barrier242, gene therapy or 
intravitreal delivery of caspase inhibitors would be the only means to suppress caspase 
activity in rd1-Tsc1cKO cones.
 
We employed a straightforward approach of inhibiting mTORC1 activity using 
rapamycin to promote autophagy in rd1-Tsc1cKO cones. Similar to studies in various 
tissues with TSC loss191,192,195, rapamycin treatment completely eliminated p62 
accumulation and restored cone-arrestin expression in wild type mice (Figure 3.6). 
However, under conditions of disease, rapamycin demonstrated a dose-dependent effect 
on cone survival. These results are fascinating because they indicate how cell survival 
can be controlled by manipulation of mTORC1 activity. While studies so far have only 
shown how rapamycin reduces tumorigenesis of TSC tumors192, it is possible that 
sporadic administration of rapamycin may enhance tumor survival since it allows tumor 
cells to rebalance their metabolic demands under conditions of low nutrients and hypoxia 
that cells in tumors experience274. The chronic effects of constitutive mTORC1 activation 
may also explain why TSC tumors are mostly benign, as opposed to tumors with loss of 
function mutations in Pten, which are highly aggressive and metastatic147,271. Pten is also 
further upstream in the insulin/mTOR pathway and therefore, its loss may alter additional 
signaling pathways that aggravate tumorigenesis, however the efficient balancing of cell 
metabolism through mTORC1 may also be a contributing factor to the difference in their 
tumorigenic effects. This point is exemplified in the linear regression analysis of cone 
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survival over a period of one year, where loss of Tsc1 causes a very sharp decline in cone 
survival, as opposed to Pten loss (Figure 3.11). 
 
Limitations of the mouse model in vision research: While the mouse is an excellent 
model organism to perform elegant genetic analyses due to shorter gestation times when 
compared to other mammals, they may not be the best system to study vision. This is 
because mice are primarily nocturnal animals and rely more on olfaction for navigation, 
as opposed to vision. Therefore, our laboratory has not had any success in using behavior 
tests such as the Cliff test to assess if loss of Tsc1 improves visual behavior. The ERG 
serves as the only mode of assessment of visual function, which also become difficult to 
perform in rd1 mice because degeneration progresses very rapidly. Further, mice lack the 
macula at the center of the retina, which harbors the cone-rich foveal pit. However, 
outside the macula the distribution of rods and cones is similar between humans and 
mice. Therefore, while the progression of cone death is from the center to the periphery 
in mice, in humans the central region that is most abundant in cones is always the last 
area to degenerate. Therefore, humans RP patients almost always retain some amount of 
central vision even at the end stages of the disease. Therefore, approaches that delay cone 
death may at least serve to preserve central vision in humans if administered at late stages 
of the disease.  
 
When compared to mice, the canine retina serves as a better model to study RP with 
about 10 different canine models that are currently in use for the study of retinal 
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degeneration. While dogs also lack the macula, they possess a region known as area 
centralis that is rich in cones and therefore, more closely resembles the human retina.  
Further, since dogs are more dependent on vision as opposed to mice, visual behavior and 
visual acuity tests are feasible. Proof of principle studies for various gene replacement 
strategies have met with great success in dogs with restoration of visual function and 
behavior, even when the gene was delivered at late stages of disease (also discussed in 
introduction). Further, since the size of the canine retina is larger than the mouse retina, it 
is easier to perform multi-focal ERGs, which is used to assess cone function across 
different regions in the retina. Therefore, for applications like gene therapy where only a 
portion of the retina may be infected with the therapeutic gene, multi-focal ERGs allow 
for the assessment of visual responses specifically in the infected region.  Besides dogs, 
there are also cat and pig models but no known primate models for RP. Therefore, testing 
the efficiency of mTORC1-based therapies in these larger animal models would be the 
next step before moving to clinical trials in humans.   
Bench to bedside translation: Our findings are not directly translatable into a therapy, 
since cell-type specific deletion of Tsc1 or Pten is not feasible in humans. Delivery of 
silencing vectors to inhibit Tsc1 or Pten in cone PRs may also lead to undesirable effects 
if they target the adjacent RPE cells, where loss of Pten is known to induce metastasis of 
RPE cells and eventual loss of PRs298. Our results however may redirect efforts aimed at 
developing therapies for patients with RP.  Our detailed characterization of cone survival 
kinetics upon loss of Tsc1 under both disease and wild type conditions, as well as its 
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effect on autophagy highlight the potential undesirable effects of increasing mTORC1 
signaling in cone PRs. However the absence of any reduction in cone survival or function 
upon loss of Pten in a wild type background suggests that mTORC1 can be activated to 
fairly high levels in cones without causing any detrimental effects (Figure 3.10). 
Therefore, while it may seem disappointing that loss of Tsc1, which promotes an initial 
robust rescue of cones, also has toxic side effects, this may be advantageous from a 
therapeutic perspective. This is because the data suggests that sustenance of cone PRs 
over a long duration does not require a drastic increase in mTORC1 activity. 
Consequently, drugs that increase mTORC1 activity can be administered at low doses 
through the use of slow-release eye implants, similar to the ones used for CNTF 
delivery92. It is unlikely that a compound increases mTORC1 activity to the same extent 
that genetic loss of Tsc1 does and therefore, this approach may greatly benefit survival of 
cones in RP. Alternatively, rAAV mediated expression of mTORC1 target genes that 
promote glucose uptake and utilization in cones PRs may also be a feasible approach.
This approach has the advantage that over-expression may induce gene expression more 
strongly than an increase in mTORC1 activity and that one could principally improve 
glycolytic metabolism in cones without altering mTORC1 activity. However, the 
approach may have a limitation that over-expression of any one target gene may not be 
sufficient to afford cone survival and therefore, it rests on the identification of a 
minimum combination of genes that would be sufficient to achieve cone survival. For 
example, a combination of Glut1 and G6pd may be sufficient to confer survival, however 
there are limitations to the size of the gene that can be packaged into a single rAAV 
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vector and hence, this approach may require simultaneous infection of two or three rAAV 
vectors in each cone cell. Therefore, expression of transcription factors like Hif-1α that 
regulate expression of multiple glycolytic genes may be a better approach.  
 
While our study is based on the hypothesis that cones are suffering from a shortage of 
glucose and improving glycolytic metabolism is required to confer cone survival, it is 
also possible that promoting lipid synthesis to regenerate the outer segment may be 
sufficient for cone survival.  In this regard, expression of a transcription factor like 
Srebp1, which regulates the expression of various genes involved in lipid synthesis, may 
improve both cone survival and function. 
 
Since cone death begins only after about 90% of rods have died and is tightly linked to 
the structural integrity of the retina, it may also be worthwhile to consider if preserving 
the structure of the PR layer would delay cone loss. In this regard, administration of self-
assembly polymers or nanoparticles may assist the formation of a matrix thereby 
preventing the collapse of the PR layer, especially when administered during early stages 
of the disease. These polymers could also be engineered to deliver therapeutic genes or 
release mTORC1-activating drugs upon assembly, which may improve the efficiency of 
cone survival.  
 
Finally, extending cone survival may also benefit other strategies that are currently being 
developed for retinal degeneration such as stem cell therapies. Since cones in RP, which 
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do not have any genetic defects, die following the loss of rods, the newly transplanted 
cells may also face the same fate if we cannot efficiently prevent their death.  
 
Implications of mTORC1 in other retinal degenerative diseases: Besides being a 
mutation independent approach to prolong vision across various RP mutations, it is 
interesting to note that mTORC1 activation can also be employed to treat age-related 
macular degeneration (AMD), which is the most common cause of blindness. While RP 
has a clear genetic etiology, AMD is caused by a multitude of genetic and environmental 
factors and primarily affects the macula, which is the cone-rich region that confers high-
acuity vision in humans299. The disease is initially characterized by the accumulation of 
drusen, which are lipid deposits on the basal side of the RPE, thereby impinging nutrient 
transfer from the choriocappilaries to the RPE cells300. This affects RPE cell health and 
function. Because RPE cells are the main source of nutrients and required for various 
functions of PRs, a reduction in RPE cell function also affects PRs. Our laboratory 
employed an advanced stage model of AMD, known as geographic atrophy, where RPE 
cells are lost in patches across the retina. We interrogated whether activation of mTORC1 
can also improve survival of PRs when they are deprived of their primary source of 
nutrients, the RPE cells301. Indeed, activation of mTORC1 by loss of Tsc1 promoted 
survival of both rod and cone PRs in a model of geographic atrophy, where RPE cell 
death was chemically induced302. Further, the mechanism of protection involved an 
upregulation of glycolytic genes such as HkII and G6pd, suggesting that the same 
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approach of improving cone metabolism in RP can also be employed to treat the most 
common form of retinal degeneration.  
Similar to AMD, diabetic retinopathy (DR) is also a multifactorial disease that does not 
have a clear genetic cause, and commonly develops in people with diabetes mellitus. In 
fact, patients with diabetes show a reduction in visual function before developing any 
clinical signs of DR303. Diabetes involves a systemic deregulation of the insulin/mTOR 
pathway and therefore insulin signaling is likely affected in all retinal neurons including 
cone PRs304,305. We have shown that loss of Tsc1 induces a progressive decline in cone 
function (Figure 3.1). Similarly, while loss of mTORC1 or mTORC2 does not affect cone 
function, concurrent loss of both mTOR complexes also causes a reduction of cone 
function282. The decline in cone function upon either activation or removal of mTOR 
signaling may thus explain why patients with diabetes also experience signs of visual 
dysfunction.  
Further, while cone death in RP progresses from the periphery to center in humans, in 
both DR and AMD, PR death is regional and can be randomly distributed across the 
retina. While DR and AMD are both caused due to different factors, it is likely that once 
a certain number of PRs in a region die, the remaining surrounding ‘healthy’ PRs are also 
affected, similar to cones in RP13,306. Therefore improving metabolism of PRs may not 
only be useful to prolong survival of cones in RP, but also prolong vision in various kinds 
of retinal degenerations, thereby improving the quality of life.  
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Increasing mTORC1 activity, more than meets the eye:  The mTOR pathway in 
frequently deregulated in diseases like cancer, where rapamycin and other catalytic 
mTOR inhibitors are used to suppress its activation. On the contrary, increasing 
mTORC1 activity may be beneficial in other diseases/conditions besides retinal 
degeneration. For example, conditions where muscle health and function are affected 
such as sarcopenia or muscle atrophy may benefit from an increase in protein synthesis 
and growth driven by an increase in mTORC1 activity. Amino acids like L-leucine that 
induce mTORC1 activity are an integral component of supplements used to build muscle 
mass and hence compounds or drugs that potently activate mTORC1 may find 
application in this area. Further, it has been demonstrated that mTORC1 is a critical 
regulator of red blood cell (RBC) formation and proliferation307. Therefore, in diseases 
like anemia where RBC population is compromised, increasing mTORC1 may prove 
beneficial. Additionally, increasing mTORC1 activity in tissues like the pancreas 
promotes increase in β-cell mass and insulin synthesis308, which may help in the control 
of diabetes. Lastly, in neurodegenerative diseases such as amyotrophic lateral sclerosis 
and Parkinson’s disease that are characterized by the accumulation of protein aggregates, 
inhibition of mTORC1 activity has been shown to confer neuroprotection by promoting 
autophagy, which results in the clearance of aggregated proteins309,310. However, some 
studies report that inhibition of mTORC1 activity accelerates neurodegeneration311, since 
its inhibition over time may also affect neuronal metabolism in general, similar to loss of 
mTORC1 activity in rd1 cones. A different approach to tackle the problem would be to 
consider if an overall boost in neuronal metabolism mediated by a moderate increase in 
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mTORC1 activity could benefit neuronal survival, as opposed to suppressing mTORC1. 
Therefore, there may be more to increasing mTORC1 activity than meets the ‘eye’ and 
research in the coming years will reveal novel applications of this approach.  
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CHAPTER V 
 
Materials and Methods
Study approval. The IACUC of the University of Massachusetts Medical School 
approved the animal study. All procedures involving animals were performed in 
compliance with the Association for Research in Vision and Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research.  
Animals. Mice were maintained on a 12-hour light/12-hour dark cycle with unrestricted 
access to food and water. Lighting conditions were kept constant in all cages, with 
illumination ranging between 10 and 15 lux. The Pde6brd1/rd1 (rd1), Casp2–/–, C57BL/6J, 
Ptenc/c, Tsc1c/c were purchased from The Jackson Laboratory39,147,237,271. The M-opsin-Cre 
(cone-specific Cre line using the human medium wavelength promoter), Raptorc/c, 
Rictorc/c, and Rho–/– mice have been described previously by Yun Z. Le, Michael N. Hall, 
Markus A. Rüegg, and Janis Lem, respectively261,262,267. Genotyping was performed as 
described in the original publications. None of the mice used for analysis were on an 
albino background, and all mice were genotyped for absence of the rd8 mutation312. To 
dissect the role of the insulin/mTOR pathway in cone survival, the conditional allele was 
first crossed with the cone-specific Cre-driver line and then with the rd1 line to generate 
Cre– and Cre+ rd1–conditional allele (cKO) lines. In some cases, double-conditional 
alleles were also generated. The Cre+ and Cre– lines were crossed with each other (e.g., 
rd1-Ptenc/c X rd1-Ptenc/c M-opsin-Cre+/–) to generate the Cre+ and Cre– littermates that 
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were used for analyses. Because various strains were interbred, strain background 
differences may account for the slight variations in cone survival in Cre– animals at 2 
months of age. Nonetheless, our data clearly show that mTORC1 was required for cone 
survival during disease, since loss of Raptor always accelerated cone death, while 
increasing mTORC1 activity consistently improved cone survival. Because loss of Casp2 
did not allow us to compare Cre– and Cre+ littermates, we generated a congenic rd1 
Casp2–/– line to study the effect of loss of CASP2 on cone survival. The Casp2–/– allele 
was on a C57BL/6J background and was crossed with rd1 C57BL/6J mice that were 
generated by backcrossing the Pde6brd1/rd1 allele of the FVB strain with C57BL/6J mice 
for 10 generations. rd1 C57BL/6J mice were then compared with rd1 Casp2–/– C57BL/6J 
mice to quantify cone survival. 
Quantification of cone survival. Retinal flat-mount images for the cone survival 
quantification were acquired by tiling individual images taken at ×16 magnification 
(Leica DM5500) over the entire retinal surface area with an automated scanning stage. 
For all cone survival quantifications in the rd1 and Rho-/- models of RP, the percentage of 
surviving cones is based on a calculation of the percentage of the retinal surface area that 
is covered by cones. To determine the area that was covered by cones, we used the 
staining detected by the cone arrestin antibody (Figure 5.1 A and B, red signal in the first 
column, gray scale signal in second and white signal in last column) as a proxy for 
surviving cones. To determine the retinal surface area, retinae were stained with PNA-
coupled FITC (Figure 5.1 A and B, green signal in the first and last columns and gray 
scale signal in the third column) at a dilution that was 3 times higher than that used for all 
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other staining procedures, with the goal to only elicit sufficient background fluorescence 
to highlight the entire retinal surface area rather than detect cone OSs. The ratio of red to 
green pixels, which was calculated using CoLocalizer Pro software313 (CoLocalization 
Research Software) with its integrated background correction, thus directly representing 
the percentage of the retinal surface area that was covered by the cone arrestin antibody 
staining. Before calculating the percentage of colocalization of red and green, the upper 
and lower thresholds of each signal were adjusted, such that only cones were visible in 
the red signal (Figure 5.1 C and D) and the entire retina was visible in the green signal. 
To calibrate the percentage of colocalization of red and green signals on an rd1-mutant 
background to the actual percentage of surviving cones, we performed a real cone count 
rather than determining the percentage of cone arrestin staining that covered the retina in 
WT mice. The reason for this is that during degeneration, cone arrestin was also found in 
the cell body, resulting in a different pattern of expression; thus, the percentage of 
colocalization was different when compared with that in retinae of WT mice (Figure 5.1 
E and F). A cone count was performed across 3 WT retinae and across 3 rd1 Tsc1cKO 
retinae at P21 (Figure 5.1 H and I). The mutant strain and time point were chosen at P21, 
since at this point, cone death had just started, and the percentage of colocalization of red 
and green signals was the highest upon loss of TSC1 (52.7%). The actual cone count in 
WT retinae was in agreement with published data314 and revealed that at P21, 95.2% of 
cones were still present in the rd1 Tsc1cKO retinae when compared with those in WT 
retinae, meaning that 52.7% of colocalization (red to green signal) corresponds to 95.2% 
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of cones. These numbers were used to calibrate all colocalization data representing cone 
survival.  
 
Figure 5.1: Cone Survival analysis (legend on following page) 
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Figure 5.1: Cone Survival analysis. (A,B) Examples of tiled retinal flat mounts used for cone survival 
quantification at 2 months of age in rd1-Tsc1c/c;Cre ± mice (Compare to Figure 2.6). First column, actual 
scan showing cone arrestin (red signal) and the diluted FITC-PNA signal (green). Second and third 
columns gray scale images of cone arrestin and PNA-FITC, respectively.  Last column, actual 
colocalization as seen after analysis (white signal) with Colocalizer Pro. Percentage of cone arrestin 
positive cones is indicated in panel. (C) Example of the actual image resolution obtained by the tile scan 
used for the cone survival quantification. Shown is cone arrestin staining in gray scale.  (D) Same image as 
in (C) after adjusting the upper and lower thresholds such that only cones are visible (same as second 
column in A and B). After this initial adjustment images were used to calculate colocalization in 
Colocalizer Pro. (E-F) Example of retinal flat mount stained for cone arrestin (red signal) and PNA (green 
signal) in a wild type (E) and rd1 mutant (F) background. In left half of each panel PNA has been removed 
to better visualize cone arrestin staining. In wild type less red signal is seen, as cone arrestin is in the inner 
an outer segments. Therefore colocalization values of red versus green in rd1 cannot be calibrated with 
colocalization values obtained in wild type. (G) Cartoon of the 5 sectors used to count cones and location 
of squares in which cones were counted. (H) Average cone count per retina (n=3) for genotypes and ages 
indicated. (I) Percentage representation of cones per retina of values in (H) where wild type is set at 100%. 
Percentage of cone survival obtained in the rd1-Tsc1cKO at 2 months of age is similar between the counting 
method (75.8% ± 3.7%) and the colocalization method (77.6% ± 3.9%; compare to Figure 2.6). (H, I) 
Numbers in bars: actual value of graph rounded to the next number. Error bars: SD.  
To validate the method, we counted cones in retinae of rd1-Tsc1cKO mice at 2 months of 
age (Figure 5.1 G and I). This time point was chosen because upon loss of TSC1, cone 
survival at 2 months of age is still quite homogenous, rather than demonstrating a patchy 
pattern of survival, thus making it more accurate to determine the number of cones across 
the entire retina by counting individual fields. The colocalization and actual cone count 
data for mice at 2 months of age were in agreement, with no statistically significant 
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difference between them (77.6% ± 3.9% vs. 75.8% ± 3.7%, respectively), indicating that 
the colocalization method can be used to determine the percentage of surviving cones. 
The method of quantifying cones by colocalization over the entire retinal surface, rather 
than counting the number of cones in a few individual fields, was chosen because cone 
degeneration is quite patchy, progressing from the center to the periphery. Therefore, 
counting a few individual fields, even if always done in the exact same location, is not 
likely to properly represent the number of surviving cones. Thus, this method is 
independent of the degeneration pattern and the orientation of the retina. 
For quantification of cones by cone count, retinae were first divided into 5 different 
sectors with increasing radiuses of 500 mm per sector (Figure 5.1 G). Cones were then 
counted manually in 4 squares per sector (20 squares/retina), each square measuring 
40,000 mm2, to determine the average cone density per sector (cones/mm2). The average 
cone density per sector was then multiplied with the sector surface area to obtain the 
number of cones per sector. The surface area of each sector was calculated as the sector 
surface area of a sphere. The total number of cones per retina was then obtained by 
adding the number of cones across the 5 sectors. The numbers shown represent an 
average of 3 retinae per genotype and age. The same method was used to count cones in a 
wild type background in Chapter III.  
Electroretinography. ERG was performed using the Espion E3 console in conjunction 
with the ColorDome (Diagnosys LLC). Mice were anesthetized by an i.p. injection of a 
ketamine-xylazine (100 mg/kg and 10 mg/kg, respectively) mixture. One drop each of 
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phenylephrine (2.5%) and tropicamide (1%) was applied for pupil dilation 10 minutes 
before to recording. Animals were kept on a warming plate during the entire ERG 
procedure to maintain body temperature at 37°C. Photopic ERGs were recorded after 
light adaptation with a background illumination of 34 cd/m2 (white 6500 K, produced by 
a Ganzfeld stimulator) for 8 minutes. For rd1 mice, flashes were presented at 1-minute 
intervals with a pulse length of 4 ms, and each recording consisted of a single flash of 35 
cd × s/m2. For mice in a wild type background, each recording consisted of 10 single 
flashes of 10 cd s/m2, with flashes presented at 1 sec intervals. In both cases, six to nine 
trial recordings were averaged.  
Histological methods. For antibody staining on retinal whole mounts, retinae were 
dissected in PBS, fixed for 30 min in 4% paraformaldehyde/PBS, washed 3 × 10 min in 
PBS, washed for 1 hr in PBT (PBS, 0.3% Triton 100), blocked for 1 hr in PBTB (PBT, 
5% BSA), incubated overnight at 4°C with primary antibody in PBTB, washed 3 × 20 
min with PBTB, incubated 2 hr with secondary antibody in PBTB, washed 5 × 20 min in 
PBT. Triton was replaced by 0.1% Saponin for staining procedures involving autophagy 
and lysosomal proteins. For sections, after fixation, retinae were equilibrated in 
increasing sucrose concentrations (from 5% to 30% sucrose/PBS), mounted in OCT 
(Optimal Cutting Temperature, Fisher), frozen, sectioned, re-hydrated in PBS for 30 min, 
and then the same procedure was used again as for whole-mount starting with the 1 hr 
wash step in PBT. CASP2 activity on retinal whole mounts was detected using the Green 
FLICA Caspase 2 Activity Kit (catalog 918; ImmunoChemistry Technologies) according 
to the manufacturer’s instructions. Briefly, retinae were incubated in DMEM media with 
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the detection reagent at 37°C for 30 minutes, followed by 2 washes of 5 minutes each in 
apoptosis wash buffer. Retinae were then fixed and processed for antibody staining as 
described. Antibody stainings were performed in TBS buffer for phospho-specific 
antibodies and in PBS buffer for all other antibodies. The following primary antibodies 
and concentrations were used: rabbit α–p-AKT (Thr308) (1:1,000; catalog 2965); rabbit 
α–p-AKT (Ser473) (1:1,000; catalog 4060); rabbit α–p-S6 (Ser240) (1:300; catalog 
5364); rabbit α–p-S6 (Ser235/236) (1:300; catalog 4856); rabbit α-PKM2 (1:300; catalog 
4053); rabbit α-HK2 (1:300; catalog 2867) rabbit α–FOXO3A (1:300; catalog 12829); 
rabbit α–mTOR (1:500; catalog 2983); rabbit α–p-ULK1 (Ser757) (1:300; catalog 6888); 
rabbit α–p-ULK1 (Ser555) (1:300; catalog 5869); rabbit α–p-AMPKβ1 (Ser182) (1:300; 
catalog 4186); rabbit α–ATG12 (1:300; catalog 2011) (all from Cell Signaling 
Technology); rabbit α–p-SGK (Ser422) (1:300; catalog ab55281); rabbit α-G6PD (1:300; 
catalog ab993); rabbit α-ME1 (1:300; catalog ab97445); rabbit α-Ki67 (1:300; catalog 
ab15580); rabbit α–ALFY (WDFY3) (1:500; catalog 84888) (all from Abcam); rat α–
LAMP1 (1:500; catalog 1D4B-c) and rat α–LAMP2 (1:500; catalog GL2A7-c) from 
Developmental Studies Hybridoma Bank; guinea pig α–p62 (1:300; catalog GP62-C) 
from Progen; goat α–short wave opsin (SW OPSIN) (1:500; catalog 14363) from Santa 
Cruz; rabbit α–HIF-1α (1:300; catalog ab1536; R&D Systems); rabbit α-GLUT1 (1:30; 
catalog GT11-A; Alpha Diagnostics); mouse α-Cre (1:500; catalog MMS-106P; 
Covance); goat α–short wave opsin (SW OPSIN) (1:500; catalog 14363; Santa Cruz); 
rabbit α–cone arrestin (1:300; catalog AB15282); rabbit α–red-green opsin (1:300; 
catalog AB5405); mouse α–Ubiquitin (1:500; catalog 1510) (all from EMD Millipore) 
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and fluorescein-labeled peanut agglutinin lectin (PNA) (1:500; catalog FL-1071; Vector 
Laboratories). All secondary antibodies (donkey) were purchased from Jackson 
ImmunoResearch and were purified F(ab)2 fragments that displayed minimal cross-
reactivity with other species. 
Quantitative real time polymerase chain reaction (qRT-PCR). RNA was isolated 
using TRIzol (Life Technologies) as described previously. Three biological samples of 
each genotype were analyzed, and each sample consisted of retinae from 2 different 
animals. One microgram of total RNA was used for reverse transcription cDNAs were 
generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics), 
and SYBR green–based qRT-PCR (Kapa Biosystems) was performed using the Bio-Rad 
CFX96 Real-Time System. Samples were run in duplicate and normalized to β-actin 
using the 2–ΔΔCt method. The primer sets used are provided in provided in the table below.  
 
Table 5.1: List of primer sequences 
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Western blot analysis. Retinae from 2 animals were pooled and homogenized by 
sonication in ristocetin-induced platelet aggregation (RIPA) buffer containing protease 
and phosphatase inhibitors (cOmplete Protease Inhibitor Cocktail and PhosSTOP 
Phosphatase Inhibitor Cocktail; both from Roche Diagnostics). Protein concentration was 
assessed using a Protein Assay Kit (Bio-Rad), and 10 μg protein was loaded per lane. 
Proteins were separated on a 4%–20% Tris-Glycine gradient gel (Bio-Rad) at 170 V and 
transferred onto a nitrocellulose membrane for 2 hours at 4°C with a current of 150 mA. 
Membrane was blocked for 1 hour at room temperature in 5% fat-free dry milk powder, 
incubated with primary antibody overnight at 4°C, washed 3 times for 20 minutes each 
wash at room temperature, incubated with an HRP-coupled secondary antibody 
(1:10,000; Santa Cruz Biotechnology Inc.) for 2 hours, and washed 3 times for 20 
minutes each wash at room temperature. Signal was detected with SuperSignal West 
Dura (Pierce Biotechnology). All incubations were performed in the presence of 0.1% 
Tween-20 and 5% fat-free dry milk powder. Incubations were performed either in TBS 
buffer for phospho-specific antibodies or in PBS buffer for all other antibodies. The 
following primary antibodies were used: rabbit α–p-AKT(308) (1:1,000; catalog 2965); 
rabbit α–p-AKT(473) (1:1,000; catalog 4060); mouse α-AKT (1:1,000; catalog 2967); 
rabbit α–p-S6 (1:1,000; catalog 5364); and rabbit α-S6 (1:1,000; catalog 2217) (all from 
Cell Signaling Technology); mouse α-β–actin (1:2,000; catalog A5316; Sigma-Aldrich); 
mouse α-CRE (1:2,000; catalog 69050-3; Novagen); rabbit α-cone arrestin (1:1,000; 
catalog AB15282; EMD Millipore); rat α-CASP2 (1:1,000; catalog ALX-804-356; clone 
11B4; Enzo Life Sciences); and mouse α- β-tubulin (1:2,000; catalog 8328) from Sigma-
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Aldrich. For the western blots depicted in Figure 3.7, instead of fat-free milk powder, 
Odyssey Blocking Buffer (catalog 927-40000) from LI-COR was used for blocking and 
antibody incubations. No detergent was added during blocking and antibody incubations. 
Primary antibodies used were same as above while secondary antibodies were infrared 
dye-conjugated (1:10,000; LI-COR). Membrane was scanned on an Odyssey Infrared 
Scanner from LI-COR to detect signal.  
NADPH measurement. NADPH was measured using the Fluoro NADP/NADPH kit 
from Cell Technology Inc. (NADPH100-2). The assay was performed in triplicate using 
3 biological samples, with each biological sample consisting of 3 retinae. Retinae were 
dissected in DMEM media, rinsed with 1X PBS, and processed following the 
manufacturer’s instructions. Retinae were sonicated after the addition of the lysis buffer 
to ensure efficient dissociation. 
Cell culture. Casp2 was amplified by PCR (forward: 
5′ATGGCGGCGCCGAGCGGGAGGTCG-3′; reverse: 5′-
TCACGTGGGTGGGTAGCCTGGG-3′) from a C57BL/6J retinal cDNA library. The 
PCR product (1359 bp) was subcloned into the pGEM-T easy vector (Promega) and 
sequence verified. The Casp2 cDNA was then cloned into an rAAV2 plasmid carrying a 
CMV promoter and the SV40 polyadenylation site. HEK293 cells were transfected with 
PEI (23966; Polyscience Inc.) and maintained in regular DMEM media containing 10% 
FCS and a penicillin-streptomycin mixture. The same media were used to maintain the 
Y79 cell line. Protein extractions were performed as described above. 
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Retinal explant culture. Retina was dissected free from other ocular tissue in PBS and 
then incubated either in regular DMEM media or glucose-free DMEM media. Fetal calf 
serum was added at 10% (vol/vol) in both cases. Incubation was performed for 2 hours at 
37°C and 5% CO2. Thereafter retinae were fixed and processed for antibody staining as 
described. 
Autophagy flux, mTOR and LAMP quantifications. The mCherry-GFP-LC3 vector315 
(Plasmid: Claudio Hetz; packaging: UMass Vector Core, rAAV9) was injected 
subretinally at birth (1μL of 1X1013 genome copies/mL) as described previously316. 
Retinae were harvested at 2 months of age and processed as described. Images from Cre- 
and Cre+ retinae were acquired (100x) at the same exposure and manual counting of the 
GFP and mCherry spots was performed in a blind manner. The same method was used to 
assess mTOR and LAMP2 colocalization as well as for LAMP1/2 counting. All images 
were acquired on a Leica DM5500 fluorescence microscope.  
Rapamycin and trehalose administration. Rapamycin was diluted in 50% Ethanol to 
10 mg/ml. Prior to injection, the solution was diluted to a concentration of 2 mg/ml in 
50% Ethanol. All mice were treated with 2mg/kg body weight of rapamycin by intra-
peritoneal injections. Mice were either injected at 5-day intervals beginning at P28 until 2 
or 4 months of age, or at P28, P35, P49, P63, P77 and P105 for the 6-injection regimen, 
or at P28 and P90 for the two-injection regimen. 50% Ethanol was used as the vehicle 
control. Trehalose (100%, Swanson Ultra) was administered at libitum in drinking water 
(4% w/v) between P28 and 4 months of age.  
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Statistics. The Student’s t test was used for statistical analyses. P values of less than 0.05 
were considered statistically significant. If not otherwise noted in the figure legend, all 
error bars represent the SEM.  
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